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ABSTRACT 
Stroke is a leading cause of death and disability. Globally, 15 million people suffer a stroke 
each year, of whom more than 5 million die, and a further 5 million are left permanently 
disabled. Current treatment options offer modest benefits, and there is a pressing need for 
new and effective treatments.  
 
Stem cell therapy is a well-established treatment modality for haematological diseases, with 
its use now being explored in different disease processes, including neurological diseases, 
as well as vascular conditions such as ischaemic heart disease and peripheral vascular 
disease. Promising results have been seen in animal models of stroke, with evidence of 
significant functional benefits. Translation to the bedside, however, is in its infancy.   
 
Bone marrow is an attractive source of stem cells, being easily accessible, and suitable for 
autologous use. CD34
+
 cells represent a subset of bone marrow derived mononuclear cells 
which have been studied in pre-clinical models of stroke. This study investigates the 
potential therapeutic role of autologous CD34
+
 cells in acute ischaemic stroke patients in a 
Phase I clinical trial. 
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Chapter One 
 
General Introduction 
1.1 STROKE 
A stroke is caused by interruption of the blood supply to the brain, either due to blockage 
from thrombosis or embolism (ischaemic stroke) or due to leakage of blood from a 
haemorrhage. The lack of oxygen delivered by blood results in generalised cell death in 
both neuronal and glial cell populations. Depending on the region of the brain affected, a 
stroke may cause a variety of clinical features such as, unilateral paralysis, speech 
impairment, visual impairment, coma, or death. Stroke can be classified into either 
ischaemic or haemorrhagic, with ischaemic strokes accounting for over 80% (Bamford et 
al; 1990).  
 
1.1.1 Epidemiology and Risk Factors 
Stroke is the second most common single cause of death worldwide (after ischaemic heart 
disease) and is the commonest cause of adult disability. In the UK, there is a stroke every 5 
minutes, and on a global basis it causes over five million deaths in the world each year. 
Moreover, in Europe, a quarter of a million people will become disabled after their first 
stroke each year. Even if age specific stroke incidence remains stable or falls slightly, as 
more people live into old age, the number of new cases of acute stroke per year will rise. 
 
Important modifiable risk factors for stroke include high blood pressure, atrial fibrillation 
and carotid artery stenosis. Other risk factors include diabetes, hypercholesterolaemia, 
smoking, obesity and excess alcohol consumption. 
 
1.1.2 Clinical symptoms and diagnosis 
A stroke is an acute vascular event, with symptoms typically occurring rapidly, over 
seconds to minutes. The type of symptoms will depend on the region of the brain affected. 
Strokes which affect the anterior circulation (carotid artery territory), may produce 
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symptoms and signs which include unilateral motor weakness or sensory loss, unilateral 
visual field defect and speech disturbance. Strokes affecting the posterior circulation 
(vertebrobasilar territory) may produce symptoms of vertigo, incoordination, slurred speech 
and visual disturbance such as diplopia.  
 
Diagnosis is made by clinical history and examination, with confirmation provided by 
imaging, typically CT (computed tomography) or MRI (magnetic resonance imaging) 
scanning. 
 
1.1.3 Current therapies 
Although recent advances have substantially improved stroke management, current acute 
treatment options offer only modest effects. Aspirin provides only a 1% absolute reduction 
in mortality rate. Thrombolysis with tissue plasminogen activator, used for the treatment of 
acute ischaemic stroke, can provide substantial benefits, potentially reversing (or partially 
reversing) the damaging effects of the stroke. However, it is only applicable within a 
narrow time frame (licensed up to 4.5 hours post-onset of symptoms), with only ~5% of 
stroke patients in England receiving the treatment annually (Intercollegiate Stroke Working 
Party, 2011). Other hyperacute treatments include endovascular procedures such as clot 
retrieval, though these are yet to be proven in the randomised controlled trial setting. 
 
Secondary prevention strategies for ischaemic stroke include antiplatelet therapy, using 
aspirin combined with dipyridamole, or more commonly clopidogrel monotherapy. 
Alternatively anticoagulation is used in those patients with underlying atrial fibrillation. 
Patients with symptomatic carotid stenosis should be considered for early carotid 
endarterectomy. Tight blood pressure control and lipid lowering are other essential 
considerations, which have been shown to reduce the recurrence of stroke (Rothwell et al; 
2011).  
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1.1.4 Recovery after Stroke 
After a stroke, about half of patients will make a good functional recovery, whilst 20-30% 
will be left with some degree of functional disability, such that they are dependent on others 
for everyday activities (Bamford et al.; 1990). Recovery tends to occur maximally in the 
first 3 months after the event, plateauing out at 3-6 months, though some gains will still 
occur at 1-2 years after the stroke.  
 
Recovery can be monitored clinically with the aid of different stroke assessment scales. 
Such scales allow objective measurement of various domains of stroke recovery. 
Neurological deficit can be measured using the NIH (National Institutes of Health) Stroke 
Scale, which is a brief, reliable assessment tool that can be administered by neurologists 
and non-neurologists alike, and is known to be an early predictor of outcome after stroke 
(Adams et al; 1999). Degree of disability, or dependence in activities of daily living, can be 
measured using the Modified Rankin Scale (mRS). This assessment tool provides a good 
overall assessment of disability, which is easy and quick to measure. Both the NIHSS 
(Goldstein et al; 1997) and mRS (Lai et al; 2001) have also been validated in clinical trial 
settings, the latter being the most widely used clinical outcome measure in stroke trials.  
 
Most patients, therefore, show some spontaneous recovery after a stroke, which can be 
further improved by interventions such as neurorehabilitation. However, this recovery is 
often incomplete. The rate and degree of recovery depends on a number of factors, 
including age at onset, location and size of lesion, and comorbidity. Stroke therefore 
remains a major source of adult disability and there continues to be a compelling need for 
new and effective treatments for severe, disabling stroke. 
 
1.2 REGENERATIVE POTENTIAL OF THE BRAIN 
Cells of the brain and central nervous system were, until recently, thought to be incapable 
of regeneration. However, in the last decade, evidence of neurogenesis in the human adult 
brain has been demonstrated in the dentate nucleus of the hippocampus and the sub-
ventricular zone (Eriksson et al., 1998;Curtis et al., 2007). This has formed the basis for 
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experimental work investigating the potential role of cell transplantation therapy in the 
treatment of various neurological diseases, in particular ischaemic stroke. 
 
A recent study of patients with ischaemic stroke was able to demonstrate evidence of 
neurogenesis in the ischaemic penumbra, where cells were found to preferentially localise 
to the vicinity of blood vessels (Jin et al., 2006). These findings are suggestive of stroke-
induced compensatory neurogenesis, where it may contribute to post-ischaemic recovery, 
and therefore represent a potential target for stroke therapy.  
 
1.2.1 Stem Cells 
Stem cells can be defined as clonogenic cells that have the capacity to self-renew and 
differentiate into multiple cell lineages (Weissman et al., 2001). Stem cells are present 
throughout life, though differences in differentiation potential (potency) allow for further 
sub-classification.  
 
Totipotent stem cells are capable of giving rise to an entire organism, and can be derived 
from fertilized oocytes and cells of the developing zygote up to the 8-cell stage. 
 
Pluripotent stem cells can give rise to all tissue types, from any of the 3 embryonic germ 
layers, but unlike totipotent cells, cannot give rise to an entire organism. Multipotent stem 
cells are more differentiated, less plastic cells. They are able to differentiate into multiple 
types of cells, but within one organ system (e.g. blood). Oligopotent and unipotent stem 
cells have more restricted differentiation potential, with the former capable of producing 
more than one type of cell (e.g. clonal common myeloid progenitor), and the latter capable 
of producing only one mature cell type (Figure 1.1).  
 
Progenitor cells are those cells generated by stem cells, which go on to differentiate into 
mature cells (eg. endothelial progenitor cells). Unlike stem cells which can replicate 
indefinitely, they can only divide a limited number of times, and therefore lie at an 
intermediate position between stem cells and mature fully differentiated cells. 
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Figure 1- 1 Potency of different stages of stem cells (Jones, 2006) 
 
 
1.2.2 Source of Stem Cells 
Stem cells can be classified according to their source, with the 2 major types being 
embryonic stem cells and adult stem cells. The relative merits of each are presented in 
Table 1.1. 
 
Human embryonic stem (ES) cells are pluripotent, and are isolated from 5-day old human 
blastocysts. The major limiting factor to their widespread use includes ethical concerns 
regarding the use of unwanted embryos. Furthermore, embryonic stem cells can be 
characterised by their ability to form teratomas (Thomson et al., 1998) and therefore there 
is concern regarding their tumorigenicity. 
 
Adult stem cells are multipotent stem cells found in developed organisms, which are used 
to replace cells which have died or have become functionally impaired. They can be 
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obtained from adults as well as children, including from umbilical cord blood. They have 
been identified within many different organ systems, including bone marrow, brain, heart, 
skin and bone. Adult stem cells make up ~1-2% of the total cell population within a 
particular tissue type. They are usually quiescent and held in an undifferentiated state until 
they receive a stimulus to differentiate. 
 
Recent advances in stem cell research have seen the ability to transform adult stem cells 
from human skin fibroblasts into pluripotent stem cells (ES cell-like), in a phenomenon 
known as induced pluripotency (Yu et al., 2007;Meissner et al., 2007;Takahashi et al., 
2007). This is in its early stages of research, but has the potential advantage of obtaining 
pluripotent stem cells from individuals, without the ethical dilemmas associated with the 
use of embryonic stem cells. 
 
 
Cell Type Advantages Disadvantages 
Embryonic Stem 
Cells 
 
 Pluripotent 
 Immortal in vitro 
 Highly expandable 
 
 Ethical issues 
 Insufficient availability 
 Unknown risk of tumour formation 
Adult Stem Cells 
 
• Multipotent 
• Potential for Induced 
Pluripotency 
• Suitable for autologous and 
allogeneic use 
 
• Immunosuppression required for 
allografting 
• Certain types difficult to obtain e.g. neural 
stem cells 
• Expansion issues 
Table 1- 1 Relative merits of different sources of stem cells  
 
 
1.2.3 Stem Cell Therapy 
Human stem cell transplantation therapy is a now a well-established treatment for various 
malignant and non-malignant haematological diseases and some autoimmune disorders. 
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Pre-clinical studies over the last decade have demonstrated significant benefits of stem cell 
therapy in rodent models of ischaemic stroke. Translation to the bedside, however, is in its 
early stages.  
 
Clinical approaches to stem cell therapy in stroke can be broadly divided into endogenous 
and exogenous approaches. The endogenous approach aims to stimulate mobilisation of 
stem cells already present within the individual. Examples of this approach include the use 
of granulocyte-colony stimulating factor (G-CSF) which is routinely used to mobilise stem 
cells for transplantation in haematological malignancies. G-CSF has been shown to be 
beneficial in rodent models of stroke (exhibiting neuroprotective and neuroregenerative 
activity; (Shyu et al., 2004;Schabitz et al., 2003), and furthermore has been shown to be 
safe in phase I clinical trials of human stroke when used within 7 days (Shyu et al., 2006b) 
or 7-30 days post stroke (Sprigg et al., 2006). A number of phase II trials are currently 
underway to investigate its efficacy in patients with ischaemic stroke. The recently reported 
STEMS 2 (phase IIb) clinical trial showed that G-CSF given to patients 3-30 days after 
stroke onset was safe, with a trend towards reduction in MRI ischaemic volume in the 
treated group (England et al., 2012).  
 
The exogenous approach involves transplantation of the patient with stem cells delivered 
locally (e.g. direct intracerebral implantation) or systemically (e.g. intravenous), and may 
involve in vitro culture of cells for expansion of cell numbers prior to administration.  
 
1.3 STEM CELL TRANSPLANTATION IN ISCHAEMIC STROKE 
Following a stroke, all brain tissue elements (i.e. neurons, glial cells and blood vessels) are 
lost, unlike Parkinson’s disease for example, where a specific neuronal type is damaged. 
After an episode of ischemia, a characteristic pathophysiological change ensues in affected 
brain tissue.  At the core of the infarct cavity, the affected cells die rapidly by necrosis, and 
an area of surrounding tissue, the “penumbra”, contains tissue in which neurones and glia 
variably survive, or die by a mixture of ischaemic degeneration and apoptosis over an 
extended time course of days to weeks (Mattson et al., 2000).  
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Stem cell therapy for ischaemic stroke, therefore, focuses on a regenerative strategy 
required to restore not only neural elements, but supporting structures such as blood 
vessels. A number of different types of stem cells, obtained from different sources, have 
been shown to improve clinical and radiological outcomes in pre-clinical models of stroke. 
The choice of cell type for clinical trial use should consider not only efficacy, but also ease 
of obtaining the cells, issues regarding cell culture for expansion, need for 
immunosuppression, questions regarding dosage, as well as long term biological safety. 
The different types of cells are discussed in more detail.  
 
1.3.1 Neural Stem/Progenitor Cells (NSCs) 
It is now generally accepted that active neurogenesis, originating from NSCs, occurs in 
discrete areas of the mammalian adult brain throughout life, giving rise to new populations 
of neurones and glia (Temple, 2001).   Neurogenesis can be physiological, or can be subject 
to external modulation by certain conditions e.g. CNS damage, such as ischaemia.   
 
Neural stem cells (NSCs) have the capacity to differentiate into neurones, astrocytes and 
oligodendrocytes.   Transplantation of embryonic and foetal derived NSCs has been 
explored in a number of experimental stroke models (Kelly et al., 2004;Jeong et al., 
2003;Chu et al., 2004;Chu et al., 2003).  However, the use of such embryonic or foetal 
tissue is limited by ethico-legal implications, in addition to important biological questions 
regarding the potential for tumour formation associated with the use of ESCs. The 
emergence of induced pluripotency, whereby skin fibroblasts can be transformed into ESC-
like cells, may overcome these issues in future studies.   
 
Several studies have documented the isolation of NSCs from the adult rodent brain 
(Reynolds and Weiss, 1992;Wachs et al., 2003), and more recent work has extended to the 
adult human brain (Nunes et al., 2003;Arsenijevic et al., 2001).  Adult-derived human 
NSCs delivered intravenously or stereotactically surrounding the lesion, have been shown 
to survive, migrate toward the lesion and differentiate (mainly into neurones and 
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astrocytes), whilst improving functional recovery in rodent models of stroke (Kelly et al., 
2004;Reynolds and Weiss, 1992;Wachs et al., 2003). 
 
Although possible in principle, brain biopsies for isolation of adult human NSCs and 
autologous transplantation post-stroke is technically difficult, and no clinical trials utilising 
adult NSCs have been undertaken. 
 
1.3.2 Immortalised Cell Lines 
A number of human immortalised cell lines have been shown to improve functional 
outcomes after experimental stroke in rodent models. These cell lines have the advantage of 
providing an abundant source of cells for transplantation, available ready prepared, at the 
time of a stroke. Biological safety of such cell lines, however, remains a concern in the 
long-term.  
 
The immortalised cell line NTera-2 (NT2) was derived from a human teratocarcinoma 
(Andrews et al., 1984).  After several weeks exposure to retinoic acid (RA) and mitotic 
inhibitors, these cells differentiate into post-mitotic neurone-like cells, named NT2N cells 
(also known as hNT neurones) (Pleasure and Lee, 1993).   Terminal differentiation of these 
cells only occurs following transplantation into an adult brain (Kleppner et al., 1995). The 
transplantation of NT2N cells into the ipsilateral striatum of ischaemic rat brains improved 
functional recovery, with some parameters of behavioural improvement persisting for up to 
6 months post-transplantation (Borlongan et al., 1998b;Borlongan et al., 1998a;Saporta et 
al., 1999). No evidence of tumorigenicity was found following post-mortem examination of 
the rats (Kleppner et al., 1995).  
 
The CTX0E03 cell line developed by ReNeuron is a foetally derived multipotent neural 
stem cell line that is conditionally immortalized with c-myc-ER (estrogen receptor), such 
that proliferation only occurs in the presence of the drug 4-hydroxy-tamoxifen (Stroemer et 
al., 2008). It has been shown to effect a dose dependent improvement in sensorimotor 
function in rodent models of middle cerebral artery ischemic stroke, when delivered 
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intracerebrally (Stroemer et al., 2009). Of note the benefit seemed to be more pronounced 
in striatal infarcts, rather than larger cortical lesions (Smith et al., 2012).
 
 
1.3.3 Haematopoietic Stem/Progenitor Cells (HSCs) 
The use of HSCs for bone marrow transplantation is now well established. The potential 
use of these cells for the repair of other non-haematopoietic tissue such as heart and skeletal 
muscle has also been explored in pre-clinical and clinical studies (Corbel et al., 2003;Orlic 
et al., 2001;Losordo et al., 2007).  
 
Recently, bone marrow cells have been suggested to have a greater plasticity than 
previously anticipated and have been reported to cross the barrier of their commitment and 
transdifferentiate along alternate lineages.  Several reports have indicated an overlap in the 
molecular expression profiles for haemopoiesis and neurogenesis in mice (Terskikh et al., 
2001;Goolsby et al., 2003),  and evidence has suggested that subsets of adult human HSC 
can differentiate to neural cells (Mezey et al., 2000;Weimann et al., 2003) (albeit at a 
relatively low frequency), although this remains a highly contentious issue (Wagers et al., 
2002;Castro et al., 2002).  
 
Haematopoietic stem cells can be obtained from bone marrow, peripheral blood or 
umbilical cord blood. The advantage of such cells is that they are suitable for both 
autologous as well as allogeneic use, and furthermore are not associated with the ethical 
issues surrounding ESC or foetally derived stem cells. It is contentious whether these cells 
can differentiate into neuronal cells. However, pre-clinical studies of CD34
+
 cells have 
shown significant benefits in rodent models of stroke, with evidence of functional 
improvement as well as reduced infarct volume.  
 
CD34+ cells contain populations of haematopoietic stem/progenitor cells as well as 
endothelial progenitor cells (EPCs). In one study, CD34
+
 cell transplantation delivered 
intravenously resulted in increased perilesional angiogenesis and subsequent neurogenesis 
in mice, at 48 hours post-stroke (Taguchi et al., 2004). A further study investigating direct 
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intracerebral implantation of CD34
+
 cells one week after induced stroke was also able to 
show evidence of neurogenesis and angiogenesis, with differentiation of transplanted cells 
into cells expressing markers for neurons, glial cells, and vascular endothelial cells (Shyu et 
al., 2006a). 
1.3.4 Mesenchymal Stem Cells (MSCs) 
 
Mesenchymal stem cells, also known as bone marrow stromal cells, can be obtained from 
bone marrow, as well as other sources such as adipose tissue. As with HSCs, they are 
suitable for autologous as well as allogeneic use. One disadvantage of this cell type is the 
requirement for several weeks of cell culture to generate sufficient numbers, thereby 
making the use of autologous MSCs in the acute phase of stroke an unviable option.  
 
These cells have shown significant functional benefits in rodent models of stroke in the 
acute as well as chronic setting (upto 1 month post-stroke), and when delivered by a variety 
of routes (intravenous, intraarterial and intracerebral) (Chen et al., 2001;Shen et al., 2007;Li 
et al., 2001;Li et al., 2000). The mechanism of improvement remains unclear, though 
promotion of endogenous neurogenesis, reduction of apoptosis, and induction of 
angiogenesis has been demonstrated in different studies (Chen et al., 2003b;Chen et al., 
2003a). 
 
1.3.5 Bone Marrow Mononuclear Cells (BMMNCs) 
 
Mononuclear cells obtained from bone marrow contain populations of both mesenchymal 
and hematopoietic stem cells. They have been shown to reduce neurological deficits as well 
as infarct size in animal models of stroke (Brenneman et al., 2010;Giraldi-Guimaraes et al., 
2009). These cells are easy to obtain from bone marrow, and are suitable for autologous 
and allogeneic use. Transplantation with HSCs (CD34
+
 cells) or MSCs provides more 
concentrated, purer cell populations, though BMMNCs have the advantage of being easier 
to prepare and separate from bone marrow, making them theoretically more practical, 
particularly in the acute setting. Potential mechanisms of action include paracrine effects 
secreting trophic factors, as well as possibly immunomodulatory benefits (Brenneman et 
al., 2010;Sharma et al., 2010). 
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1.4 STEM CELL TRANSPLANTATION AND PUTATIVE CELLULAR 
MECHANISMS OF RECOVERY IN ISCHAEMIC STROKE 
The functional recovery seen in many experimental models following stem cell 
transplantation is likely to be mediated by several overlapping mechanisms, and 
understanding of these is crucial in order to determine the best approach for translation into 
the clinical setting.  There are a number of proposed mechanisms that have been 
investigated in pre-clinical stroke models (Figure 1.2). 
 
Integration of transplanted cells into the ischaemic brain, with replacement of lost cells is 
an unlikely mechanism of repair. Most studies have shown survival of very few 
transplanted cells following neurotransplantation, despite evidence of significant functional 
recovery. More likely is stimulation of a trophic effect on the ischaemic brain (e.g. by 
secretion of various growth factors), including recruitment of endogenous repair processes. 
Anti-inflammatory effects may also play a role (Ohtaki et al., 2008). 
 
1.4.1 Integration into host brain 
The traditional-held view of stem cell mediated recovery is that cells act via differentiation 
and formation of new cells and integrate into the damaged organ. In the field of stroke 
research, there is very little evidence for this, though in one in vivo study they were able to 
demonstrate that transplanted CD34
+
 cells showed migration towards the area of infarction, 
and expressed markers of neuronal (Nestin, MAP-2, and Neu-N) and glial (GFAP) 
differentiation (Shyu et al., 2006a). In contrast, most studies have shown the survival of few 
transplanted cells following neurotransplantation, with very little evidence that adult stem 
cells integrate into the ischaemic brain and form functional neurons with adequate synaptic 
connections. This is despite evidence of significant functional recovery, and therefore, 
neuronal differentiation and integration is unlikely to play a major role in improving 
outcome in stroke models (Chu et al., 2004; Stroemer et al., 2009).   
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1.4.2 Promotion of angiogenesis 
Angiogenesis occurs following a stroke, which may be associated with improved 
neurological recovery (Wei et al., 2001;Senior, 2001). In induced stroke models, 
angiogenesis has been demonstrated after cell transplantation with a number of different 
stem cells, including NSCs (Jiang et al., 2005), CD34
+
 cells (Shyu et al., 2006a;Taguchi et 
al., 2004), and MSCs (Shen et al., 2006;Chen et al., 2003b).  This is thought to be mediated 
by the release of various factors, particularly VEGF (vascular endothelial growth factor), 
and also by the increase in endogenous levels of other factors (such as brain-derived 
neurotrophic factor, BDNF and fibroblast growth factor, FGF) which play a role in 
neovascularisation. Direct incorporation of the transplanted cells into new blood vessels has 
also been demonstrated (Taguchi et al., 2004). 
 
1.4.3 Promotion of neurogenesis  
Following an ischaemic stroke, endogenous neurogenesis has been shown to increase, 
which is thought to represent an intrinsic host repair mechanism in response to the 
ischaemic insult  (Arvidsson et al., 2002). Such endogenous neurogenesis can be enhanced 
with the administration of cord blood cells, and mesenchymal cells (Nakatomi et al., 2002), 
though what is unclear is whether this is likely to be functionally significant. 
 
1.4.4 Reduced apoptosis  
The mechanism of neuronal and glial cell death after an ischaemic stroke involves a 
combination of necrosis and apoptosis, depending on the severity and duration of 
ischaemia.  Following prolonged or complete ischemia, necrotic cell death is likely to 
predominate, but if ischemia is transient or partial, than apoptosis predominates.  Cell 
transplantation may elicit a neuroprotective response by rescuing these apoptotic cells, 
particularly in penumbral tissue. Trophins likely to be involved in this process include basic 
fibroblast growth factor (bFGF), BDNF, VEGF and nerve growth factor (NGF). A number 
of studies have demonstrated a reduction in apoptosis in the ischaemic boundary area 
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following cellular therapy which may improve neurological recovery in experimental 
models (Chen et al., 2003a;Kurozumi et al., 2005;Llado et al., 2004). 
 
1.4.5 Reduced inflammation 
Immunomodulatory effects of transplanted cells may have a role in neuroprotection. Pre-
clinical studies have shown evidence of up-regulation of anti-inflammatory cytokines and 
attenuation of expression of pro-inflammatory cytokines in both ischemic and hemorrhagic 
stroke models (Vendrame et al., 2005;Lee et al., 2008). If an anti-inflammatory effect is to 
play an important role, delivery of the cells will need to be in the early stages of the stroke, 
during the acute inflammatory cascade.  
 
1.4.6 Promotion of other endogenous repair processes 
It is possible that transplantation of various stem cells may amplify endogenous plasticity 
responses, again mediated by the secretion of trophic factors. Neuroplasticity refers to the 
brain's ability to reorganise itself by forming new neural connections throughout life. This 
can be physiological, or alternatively may occur in response to injury such as stroke. 
Neuroplasticity is mediated mainly by axonal sprouting to form new connections, and 
stimulation of endogenous neurogenesis (Carmichael, 2006).  Synaptic plasticity can also 
occur, whereby modification and upregulation of synaptic proteins results in altered 
synaptic connections, and activation of previously silent synapses, thereby potentially 
leading to new and novel circuits (Stroemer et al., 1995).  One study suggested that intra-
arterial administration of MSCs enhanced host neuronal and synaptic plasticity, with 
increased synaptophysin expression in the ischemic penumbra (Shen et al., 2006).  A 
further study demonstrated axonal sprouting from the non-ischaemic to the contralateral 
hemisphere following the intravenous administration of human cord blood cells (Xiao et al., 
2005).  
 
In addition, other stem / progenitor cells are also increased following cerebral ischaemia.  
The stress of an ischaemic stroke has been shown to increase peripheral blood levels of 
CD34+ cells. An increase in circulating numbers of CD34+ cells may enhance homing to 
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ischaemic brain tissue and the production of trophic factors, all of which contribute to 
improved neurological function (Dunac et al., 2007). As previously mentioned, G-CSF 
which mobilises CD34+ cells into the peripheral circulation, has been shown to be 
beneficial in rodent models of stroke, where it potentially enhances this endogenous repair 
mechanism. 
 
 
  
Figure 1- 2 Stem cell types used in stroke trials & the proposed mechanism of 
action  
Abbreviations: UCB, umbilical cord blood; NSC, neuronal stem cell; BMMNC, bone marrow 
mononuclear cell; HSC, haematopoietic stem cell; MSC, Mesenchymal stem cell.  
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1.5 STEM CELL THERAPY IN STROKE PATIENTS: CLINICAL TRIALS 
Clinical trials of stem cell therapy in stroke patients are still in their infancy. There have 
been a number of recent phase I/II trials, primarily investigating the role in ischaemic 
stroke patients. However, these trials have not clearly defined the best cell type, route of 
delivery or timing of therapy, and more coordinated research is needed to better answer 
these uncertainties.  
 
All the early clinical trials have concentrated on chronic stroke patients, largely due to 
stability of patients at this time point. There are now, however, an emerging number of 
acute trials which have been completed. The pathophysiological processes and proposed 
mechanisms of action in the acute phase are quite different to the chronic phase of stroke, 
and it is not possible to extrapolate data gleaned from one setting to the other. 
 
The currently available clinical trial data utilising human stem cells is discussed further, as 
well as a discussion on ongoing trials of which there are now several scattered across 
different centres worldwide.  
 
1.5.1 Chronic Stroke Trials 
1.5.1.1 NT2N cells 
NT2N cells were the first human cells to be tested in stroke clinical trials. A phase I trial 
examined the safety of direct stereotactic transplantation of cells into patients with basal 
ganglia stroke which had occurred 6 months to 6 years previously (Kondziolka et al., 
2000). Twelve patients with stable motor deficits were treated, along with an 
immunosuppressive regimen of cyclosporine-A due to the allogeneic nature of the 
treatment. Two doses of cells were used; 2x10
6
 and 6x10
6
 cells. There was a trend towards 
improved functional outcome in the four patients who received the higher dose of cells. 
Autopsy on one patient, who died of myocardial infarction 27 months post-transplantation, 
showed apparent survival of NT2N cells in the brain (Nelson et al., 2002). Furthermore, 
PET scanning at 6 months post-transplantation showed increased metabolic activity at the 
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site of infarct in six patients (Meltzer et al., 2001). This initial safety trial led to a Phase II 
study assessing the effect of NT2N cell transplantation in 18 patients with a basal ganglia 
stroke between 1 and 6 years previously (Kondziolka et al., 2005). Stereotactic cellular 
transplantation plus two months of rehabilitation (n= 14) was compared to control patients 
who received rehabilitation alone (n =4). Six of the 14 patients who received a transplant 
appeared to show improvement on a standardised stroke scale, but this was not statistically 
significant against control patients. Of note, this trial included ischaemic (n= 9) and 
haemorrhagic strokes (n= 9). 
 
1.5.1.2 Mesenchymal Stem Cells 
The extensive pre-clinical work on MSCs described previously, led to a phase I/II clinical 
trial using autologous culture- expanded MSCs in patients with ischaemic MCA territory 
stroke (Bang et al., 2005). Thirty patients with established stroke (>1 month post-infarct) 
were randomised to receive MSCs by the intravenous route (n=5), or no MSCs (n=15). 
Cells were extracted by bone marrow aspiration and culture-expanded, prior to infusion. 
There was no cell-related toxicity related to the MSCs administration, and the authors 
suggested that functional improvement may have been better in the transplanted group 
compared with the control group, although this was not statistically significant. There were 
no significant differences between the two groups in relation to changes in infarct volume 
at 1-year follow-up. Following on from this study, the same group conducted a trial looking 
at the long-term (5 year) effects of MSC transplantation in patients with severe MCA 
territory stroke (Lee et al., 2010). Sixteen patients (versus 36 controls) were treated with 
intravenously delivered, autologous, culture expanded MSCs. There was no difference in 
adverse events between the 2 groups. Functional outcome appeared to be better in the 
treated group, with a significantly increased proportion of patients with a modified Rankin 
score of 0-3, compared to the controls.  
 
A further trial of autologous MSCs administered in ischaemic stroke patients, within 6 
months of their event, was recently reported (Honmou et al., 2011). Cells were delivered 
intravenously 36-133 days post-stroke, in an open label study of 12 patients. MSC’s were 
serum-expanded prior to infusion. The treatment was shown to be safe and feasible, with no 
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significant adverse events. Furthermore, mean infarct volume as assessed by MRI was 
reduced by >20% at 1 week post-infusion. Of note, the culturing conditions and media were 
different between the two MSC trials described above. 
 
1.5.1.3 Bone Marrow Mononuclear Cells 
Two trials utilising BMMNC’s have been reported in chronic stroke patients. One open 
label study treated 6 male patients with MCA territory ischemic stroke, within 90 days of 
the event (Battistella et al., 2011). Autologous BMMNC’s were isolated after bone marrow 
aspiration. The cells were then delivered intra-arterially, with a proportion of these labelled 
with Technetium-99m. There were no treatment related adverse events up to 6 months 
follow-up. Evidence was seen of cell migration to the brain at 2 hours post-infusion in all 6 
patients, though at 24 hours this number had dropped to 2 patients (Barbosa da Fonseca et 
al., 2010).  All patients showed improvements in their NIHSS scores by 6 months. In a 
separate study, autologous bone marrow stem cells obtained by bone marrow aspiration 
were transplanted stereotactically in 5 patients with established stroke (Suarez-Monteagudo 
et al., 2009). The procedure was well tolerated, with no adverse events up to 1 year follow-
up. 
 
There are at least 10 other ongoing or completed trials in chronic (> 4 weeks post-event) 
stroke patients which are yet to report. Details of these unreported trials are listed in Table 
1-2.  
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Table 1- 2  Summary of ongoing or completed (but unreported) chronic stroke 
trials 
Abbreviations: BMMNC, bone-marrow mononuclear cells; MSC, mesenchymal stem cells; OECs, olfactory 
ensheathing cells; EPC, endothelial progenitor cells; NR, non-randomised; OL, open label; PI and II, phase I 
and II trials; R, randomised; SB, single blind; DB, double blind; IV, intravenous; IA, intraarterial; IC, 
intracerebral. CTX0E03 and SB623 are commercially developed stem cell lines. 
Cell Type 
Study 
Design 
Expected 
No. of  
Patients 
Timing of 
Delivery 
Post-stroke 
Route of 
Delivery 
Clinical Trial 
Identifier 
Trial Status 
CHRONIC 
TRIALS(>4 
weeks post-event) 
      
CTX0E03 neural st
em cells 
PI, NR-
OL 
12 
6 months-5 
years 
IC NCT01151124 Recruiting 
MSCs 
PII, R-
OL 
30 <6 weeks IV NCT00875654 Recruiting 
CD34
+
 
PII, R-
OL 
30 6-60 months IC NCT00950521 Complete 
CD34
+
 
PI, NR-
OL 
6 6-60 months IC NCT01438593 
Not yet 
recruiting 
CD34
+
 
PI, R-
OL 
40 <1 year IA NCT01518231 Recruiting 
MSCs, EPCs 
PI/II, R-
DB 
90 5 weeks IV NCT01468064 Recruiting 
MSCs 
PII, R-
OL 
50 
1 week-2 
months 
IV NCT01461720 Recruiting 
MSCs 
PI/II, 
NR-OL 
35 >6 months IV NCT01297413 Recruiting 
SB623 
PI/II, 
NR-OL 
18 6-36 months unclear NCT01287936 Recruiting 
OECs 
PI, R-
SB 
6 
6 months – 5 
years 
IC NCT01327768 Recruiting 
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1.5.2 Acute Stroke Trials 
1.5.2.1 Bone Marrow Mononuclear Cells 
There are three currently published trials of stem cell therapy in acute stroke patients. All 3 
trials utilised BMMNC’s and were able to demonstrate safety and feasibility in the treated 
subjects. One study treated ischaemic stroke (middle cerebral artery (MCA) territory) 
patients at 24-72 hours post-event with intravenously delivered cells (Savitz et al., 2011). 
Ten patients were treated in an open label study, with no evidence of study-related serious 
adverse events up to 6 months follow-up. All patients had shifted down by at least 1 point 
on the modified Rankin Scale (mRS) at 6 months compared to at day 7. The 2
nd
 study (also 
open label) treated 20 patients with MCA territory ischaemic stroke at 3-7 days post-event, 
with the cells delivered intra-arterially (Friedrich et al., 2012). There were no procedure-
related adverse events reported up to 6 months follow-up. A good outcome (defined as a 
mRS of ≤2) was seen in 8 of the 20 patients at 90 days. The third, most recently published 
trial, treated 10 patients with BMMNCs delivered intra-arterially at 5-9 days after stroke 
(Moniche et al., 2012). This was a single blind, controlled study (10 consecutive controls; 
non-randomised). Two of the treated patients had isolated partial seizures at 3 months. 
There were no significant differences in neurological outcome between the 2 groups at final 
180 day follow-up. None of these 3 trials were powered to demonstrate efficacy.  
 
A further 5acute/subacute trials (< 4 weeks post-stroke) are ongoing or yet to report (Table 
1-3). These are utilising a variety of different cell types including BMMNC’s, MSC’s, as 
well as commercially developed stem cell lines.  
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Cell Type 
Study 
Design 
Expected 
No. of  
Patients 
Timing of 
Delivery 
Post-stroke 
Route of 
Delivery 
Clinical Trial 
Identifier 
Trial Status 
ACUTE & 
SUBACUTE 
TRIALS 
(< 4 weeks post-event) 
      
BMMNC 
PII, R-
OL 
120 7-30 days IV NCT01501773 Complete 
MSCs 
PII, 
NR-OL 
120 
7-14 days 
(infarct) 
/Or 10-21 
days(ICH) 
IV, then 
intrathecal 7 
days later 
NCT01389453 
 
 
Recruiting 
MSCs 
PI/II, 
R-DB 
78 <10 days IV NCT01091701 
Not yet 
recruiting 
MultiStem
 ®
 
PII, R-
DB 
140 1-2 days IV NCT01436487 Recruiting 
ALD-401 
PI/II, 
R-DB 
100 13-19 days IA NCT01273337 Recruiting 
Table 1- 3  Summary of ongoing or completed (but unreported) acute/subacute 
stroke trials 
Abbreviations: BMMNC, bone-marrow mononuclear cells; MSC, mesenchymal stem cells; OECs, olfactory 
ensheathing cells; EPC, endothelial progenitor cells; NR, non-randomised; OL, open label; PI and II, phase I 
and II trials; R, randomised; SB, single blind; DB, double blind; IV, intravenous; IA, intraarterial; IC, 
intracerebral; ICH, intracerebralhaemorrhage 
MultiStem
 ®
and ALD-401 arecommercially developed stem cell lines 
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1.6 STUDY RATIONALE 
There is a major unmet need for treatments that can reduce tissue injury progression, and 
enhance functional recovery in ischaemic stroke. Stem cells offer the promise of a novel 
reparative strategy for acute brain injury. Recent non-human studies of stroke utilising stem 
cell therapy have demonstrated significant behavioural recovery and in some cases reductions 
in lesion volume, as discussed previously. A variety of stem cell types have been 
investigated in this context, including CD34
+
 stem cells. CD34
+
 cells are a subset of bone 
marrow mononuclear cells (BMMNC) and act as the main endogenous source of 
haematopoietic and endothelial cell precursors. There are several lines of evidence 
suggesting that they might act as a potentially useful therapy in acute stroke.  
 
Firstly, following stroke, there is increased mobilisation of CD34
+
 cells from the bone 
marrow into the periphery (Paczkowska et al., 2005), which shows a strong positive 
correlation with clinical recovery (Dunac et al., 2007).  
 
Secondly, two trials of CD34
+
 cells in rodent models of stroke have demonstrated improved 
functional recovery, and reduced infarct size (Taguchi et al., 2004;Shyu et al., 2006a). 
CD34+ cells contain populations of endothelial progenitor cells (EPCs), which play an 
important role in endogenous vascular repair after vascular injury, and are thought to 
participate in both angiogenesis (growth of new vessels from pre-existing ones) and 
vasculogenesis (de novo formation of new vessels). In the aforementioned trials, CD34
+
 
cell transplantation resulted in increased perilesional angiogenesis and subsequent 
neurogenesis. Interestingly, Taguchi et al. also administered an anti-angiogenic compound 
7 days after CD34+ cell transplantation, and demonstrated that endogenous neurogenesis 
was suppressed by diminishing angiogenesis, thus suggesting a direct link between 
angiogenesis and neurogenesis in the repair of ischaemic brain lesions.  
 
Thirdly, a recently published clinical trial of intra-arterial BMMNC treatment for acute 
stroke showed a trend towards a positive correlation between number of CD34
+
 cells 
injected and functional outcome at 1 month. In contrast, there was no correlation between 
recovery and numbers of BMMNCs injected (Moniche et al., 2012). 
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In rodent models of stroke, intra-cerebral, intravenous, and intra-arterial routes have been 
used (Chen et al., 2001;Li et al., 2001;Li et al., 2000). Routes of administration are more 
limited in the clinical setting: intra-cerebral delivery represents an invasive approach, which 
is problematic for translation to human studies in the acute phase of stroke, whilst 
intravenous delivery of cell therapy has the drawback that the majority of these cells are 
harvested in internal organs, particularly the spleen, lungs and liver, before reaching the 
CNS (Fischer et al., 2009). Direct intra-arterial delivery, therefore represents a potential 
feasible alternative for translational studies, with better first-pass delivery of cells 
(Lappalainen et al., 2008) whilst having fewer of the risks of major surgery.  
 
Bone marrow is an attractive source of stem cells, being easily accessible, and suitable for 
autologous use, obviating the need for immunosuppression. The use of autologous cells is 
particularly advantageous as it avoids the ethical issues surrounding the use of foetal tissue.  
 
To date, there have been five published phase I trials using unselected bone marrow 
mononuclear cells (BMMNC) in stroke (Suarez-Monteagudo et al., 2009;Battistella et al., 
2011;Savitz et al., 2011;Friedrich et al., 2012;Moniche et al., 2012). These have examined 
the effect of BMMNC’s in acute and chronic stroke, using intravenous, intra-arterial and 
intracerebral approaches. They have all shown safety and feasibility in the patients studied. 
However, to date, no study has trialed CD34
+
 selected cells, via the intra-arterial delivery 
route within an early time-period post-stroke. 
 
 
 
 
 
 
 
 
 
39 
 
1.7 THESIS OUTLINE 
 
The aim of this study was to establish the safety and feasibility of autologous CD34
+
 selected 
stem cell therapy – delivered directly into the ipsilesional middle cerebral artery - in acute 
(<7 days) ischaemic stroke. Clinical and radiological outcome measures were also 
evaluated. Since this was an early-phase development study, for ethical reasons, we 
restricted our target population to those with clinically severe anterior circulation ischaemic 
stroke. 
 
The primary outcome of this study was safety and feasibility. The secondary outcome 
measures included clinical measures of neurological deficit and functional outcome, as well 
as radiological outcome measures involving qualitative and quantitative analysis of serial 
imaging. In Chapter 2, the study design and outcome measures are described. The clinical 
results are presented in Chapter 3, including a detailed description of each patient recruited 
to the study. Chapter 4 describes the imaging aspects of this study, including exploring the 
potential role of tracking transplanted stem cells.  
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Chapter Two 
Materials & Methods 
2.1 OVERALL STUDY DESIGN 
A prospective, non-randomised, Phase I study of autologous immuno-selected CD34
+
 stem 
cells therapy was undertaken in patients with acute severe ischaemic stroke to evaluate the 
safety and tolerability of stem cell transplantation in acute TACS (total anterior circulation 
stroke)  patients. 
  
For the stem cell transplantation, a bone marrow aspirate was taken to allow separation of 
the CD34
+
 stem cells by immuno-selection according to the principles of GMP in a facility 
(Hammersmith Hospital stem cell laboratory), licensed by the Medicines & Healthcare 
Regulatory Agency (MHRA) for such procedures.   These cells were then administered 
back to the patients directly by middle cerebral arterial cannulation.  
 
Recruited patients received stem cell treatment and best medical care. 
 
2.1.1 Ethics Approval 
The study was approved by the ethical committee of Hammersmith Hospital, Imperial 
College Healthcare NHS Trust, London, UK, and the MHRA. It was conducted according 
to the Declaration of Helsinki, and was registered for a trial number at ClinicalTrials.gov 
(NCT00535197).  
 
2.2 MATERIALS: CD34+ HAEMATOPOIETIC STEM/PROGENITOR CELLS 
2.2.1 CD34+ cell structure 
The CD34 molecule is a cluster of differentiation molecule present on certain cells within 
the human body, in particular hematopoietic cells. The CD34 antigen is a 115-kilodalton 
single transmembrane glycoprotein whose extracellular domain is much larger than its 
intracellular terminus (Mackie et al.; 2011). It is expressed on the cell surface of stem and 
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progenitor cells of the haematopoietic system. CD34
+
 stem cells are early non-
differentiated cells derived from bone marrow.  These cells have the property of self 
proliferation in addition to the ability to differentiate into a variety of different tissue types.  
 
CD34+ cells are therefore normally found in bone marrow and umbilical cord blood, as 
haematopoietic cells. In addition, the CD34 antigen is also expressed by small vessel 
endothelial cells and endothelial progenitor cells, and these can be found in tissues 
throughout the body, including skeletal muscle, heart, lung, kidney and brain (Krause et al; 
1996).  
2.2.2 CD34+ cell characterisation 
CD34
+
 stem cells are identified by their appearance in Romanowsky stained suspension as 
small, nucleated cells 7 to 15µm in diameter.  They bear the heavily glycosylated mucin-
like surface antigen CD34. These cells can be isolated from bone marrow samples using 
immunomagnetic or immunoflourescent techniques. 
 
CD34+ stem cells have been shown to express a number of genes relevant to 
haematopoiesis, as well as to other non-haematopoetic functions. Genes expressed which 
are relevant to stem cell functions include Oct-4 (octamer-binding transcription factor 4) 
and Nanog which are important in self renewal of embryonic stem cells, as well as CXC 
receptor 4 (CXCR-4) which is an important factor in stem cell homing. After an ischaemic 
event, peripherally secreted stromal cell-derived factor 1 (SDF-1) mediates migration and 
homing of progenitor cells to the injured area through a CXCR-4 dependent mechanism 
(Tilling et al., 2009). Other genes expressed by CD34+ cells include Angiopoietin, VEGF 
and FGF-2 which are all involved in angiogenesis, as well as Nestin, a marker of neural 
stem cells, relevant to neurogenesis. (Gordon et al; 2006; Majka et al.; 2001)  
 
2.2.3 Interactions and function 
The exact function of the CD34 antigen itself is not completely understood. CD34+ cells 
purified from bone marrow comprise only ~1% of marrow mononuclear cells, yet contain 
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precursors for all the lympho-haematopoietic lineages, and can reconstitute haematopoiesis 
in humans after myeolablative therapy. The CD34 antigen is also expressed on endothelial 
cells, where it may play a role in stem/progenitor cell localization or adhesion and cell 
migration (Krause et al; 1996).   
 
2.3 CONFIRMATION OF VIABILITY OF CD34+ STEM CELL PREPARATION 
FOR CLINICAL USE 
Study HASS-SC/10 was carried out by our laboratory (unpublished data) to assess the 
stability of immunoselected CD34
+
 cells. 
 
Two cell populations, namely, freshly collected (leukapharesis) cells, and immune-selected 
CD34
+
 cells, were tested for their storage viability at both +4
0
C and ambient temperature 
over a total period of 72 hours. 
 
Freshly collected cells were stored at +4
0
C for 24 hours then examined for total cell count 
using a haemocytometer, and viable cell count using cells with the addition of 7-AAD (7-
aminoactinomycin D) and a haemocytometer.  The results of the counts are shown in Table 
2.1 below. 
 
The minimum period either cell population would be stored, due to the need to transport 
them between sites, is 24 hours.  For this reason, the cells in this study were stored at +4
0
C 
for 24 hours and not tested at the time of collection. 
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Time point Temperature 
Total cell count 
x 10
6 
Viable cell 
count x 10
6 
Percentage viability over 
the 24 hour total count 
24 hours 4ºC 5.60 5.60 100 
24 hours 22ºC 5.70 5.70 101 
36 hours 4ºC 5.20 5.05 92 
36 hours 22
o
C 5.35 4.80 95 
48 hours 4ºC 4.90 4.45 87 
48 hours 22ºC 5.10 3.95 91 
72 hours 4ºC 4.10 3.70 73 
72 hours 22
o
C 4.90 3.45 87 
Table 2- 1  Viability of freshly collected Leukaphersis cells 
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In addition, CD34
+
 cells following immunoselection were stored at +4
o
C for 24 hours then 
tested over a period of 72 hours for stability using total CD34
+
 cell counts and viability.  
The results of this testing are shown in Table 2.2 below. 
 
 
Time point Temperature 
Total cell 
count 
Viable cell 
count
 
Percentage viability over 
the 24 hour total count 
24 hours 4ºC 1.73 x 10
5
 1.73 x 10
5
 100 
24 hours 22ºC 1.30 x 10
5
 1.3 x 10
5
 100 
36 hours 4ºC 1.5 x 10
5
 1.33 x 10
5
 86 
36 hours 22ºC 1.05 x 10
5
 9.3 x 10
4
 80 
48 hours 4ºC 1.28 x 10
5
 1.04 x 10
5
 73 
48 hours 22ºC 8.6 x 10
4
 7.2 x 10
4
 66 
72 hours 4ºC 9.3 x 10
4
 7.6 x 10
4
 53 
72 hours 22ºC 5.7 x 10
4
 4.8 x 10
4
 43 
Table 2- 2  Stability of selected CD34
+
 cells over 72 hours 
 
 
The stability studies conducted on one batch of freshly collected cells stored for 24 hours 
then tested (Table 2.2), indicate that the viability of these cells, when stored at either 4ºC or 
22ºC, is maintained above 85% of the total cell count at the 24 hour time-point and for up 
to 48 hours post collection, with only a slight reduction at 4ºC to 73% viability at 72 hours.  
This ensures that the time limit set for transport to the site of and commencement of the 
manufacturing process (48 hours) is adequate for preservation of the cells.  Cells can be 
transported and held at either 4ºC or 22ºC but normal practice is to transport and store at 
4ºC.   
 
Stability studies conducted on the immuno-selected CD34
+
 cells as shown in Table 2.3 
above seem to indicate that storage of these cells for up to 72 hours at 4ºC is preferable to 
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at 22ºC, where the rate of viability decline is greater. It would appear that the reduction in 
viability of these cells during storage is greater than the freshly collected cells.  However, 
up to 48 hours must be allowed for quality control testing of the Drug Product and transport 
to the site of patient use.  For this reason, a viability of 70% or greater is acceptable. 
 
In conclusion, freshly collected cells must be transported to and stored at the manufacturing 
site at 4ºC and the manufacturing process commenced within 48 hours of cell collection. 
The drug product, the immunoselected CD34
+
 cells, must be transported at 4ºC and infused 
to the patient within 48 hours of the completion of the manufacturing process. However it 
is recommended that the drug product be obtained and infused into the patient as 
soon as possible, to maintain maximum viability of the cells.  
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2.4 METHODS: SELECTION OF STUDY PARICIPANTS 
Patients were eligible for inclusion, if they were between 30-80 years old and had a 
clinically definite severe ischaemic stroke conforming to the Total Anterior Circulation 
Stroke (TACS; OCSP classification) phenotype. Further, specific inclusion and exclusion 
criteria are listed below: 
 
2.4.1 Patient recruitment 
Recruitment commenced in December 2007 at Imperial College Healthcare NHS Trust. 
Consecutive patients admitted to the acute stroke unit were assessed for eligibility for the 
trial. Potentially eligible patients with a TACS subtype of ischaemic stroke were 
approached for consent by myself or the co-investigators (PB, Paul Bentley; JC, Jeremy 
Chataway). Patients were seen on the stroke unit. 
 
Inclusion Criteria 
 Age range of 30-80 years old 
 Symptoms and signs of clinically definite acute stroke 
 Time of stroke onset is known and treatment can be started within 7 days of onset 
 CT or MRI brain scanning has reliably excluded both intracranial haemorrhage and  structural 
brain lesions which can mimic stroke (e.g. cerebral tumour) 
 Stroke conforming to the TACS (weakness, homonymous haemianopia and a focal  cognitive 
deficit (e.g. aphasia) or reduction in consciousness) or *PACS phenotype (2 out of 3 of 
weakness, homonymous hemianopia, and focal cognitive deficit) at maximum deficit 
 *Stroke confined to MCA territory on CT or MRI brain imaging 
 *NIHSS score >/= 8 
* Criteria added August 2010 
 
Exclusion criteria 
 Known defect of clotting or platelet function (but patients on anti-platelet agents allowable) 
 Haematological causes of stroke 
 Severe co-morbidity 
 Hepatic dysfunction 
 Renal dysfunction with serum creatinine >150 µmol/l 
 The patient is female and of childbearing potential (unless it is certain that pregnancy is not 
possible) or breast feeding 
 Hypo- or hyperglycaemia sufficient to account for the neurological symptoms; the patient 
should be excluded if their blood glucose is < 3.0 or > 20.0mmol/L 
 Patient is likely to be unavailable for follow-up e.g. no fixed home address 
 Patients with evidence of life threatening infection (e.g. HIV) or life threatening illness (e.g. 
advanced cancer) 
 Patient was already dependent in activities of daily living before the present acute stroke 
 Patients who have been included in any other clinical trial within the previous month 
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Due to a low screen: recruitment ratio, (see chapters 3 & 4 for detailed discussion) a second 
amendment was incorporated from August 2010 to broaden the criteria to include the 
Partial Anterior Circulation Stroke (PACS) subtype of ischaemic stroke including:(1) 
imaging confirmation of an infarct in the territory of the middle cerebral artery, (2) a 
significant neurological deficit with a NIHSS score of >/=8. This would allow improved 
recruitment, whilst still concentrating on a subgroup of patients at the more severe end of 
the spectrum of stroke disease. Patients with the PACS subtype were recruited onto the trial 
from August 2010. 
 
2.4.2 Informed Consent Procedure 
Potential subjects were clinically evaluated at Imperial College Healthcare NHS Trust, 
London, UK, and written informed consent was obtained (day 0, within 7 days of stroke 
onset). If the patient was dysphasic or obtunded, assent was obtained from the next of kin. 
Patients were given a minimum of 24 hours to decide regarding inclusion into the trial. 
(Patient information sheets and consent forms are shown in appendices 1-3. 
 
2.4.3 Duration of study and follow-up 
Each patient participated in the study for approximately 6 months (180 days) and all 
patients were assessed until day 180, including early withdrawal subjects. Possible reasons 
for early withdrawal were: 
 
 Patients may be withdrawn from the study if significant deterioration occurs. 
 If serious and unexpected adverse events occur that are believed to be treatment 
related. 
 Withdrawal of patient / representative consent 
 At the instigation of the Investigator when he/she believes continued participation is 
not in the best interests of the patient. 
 At the instruction of the sponsor or the regulatory authority. 
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2.5 TREATMENT REGIMEN 
A bone marrow aspirate was taken on Day 0 and CD34
+
 cells separated by immuno-
selection using standard procedures (see below). On Day 1 or 2, depending upon 
completion of the CD34
+
 stem cell immunoselection process, the cells were administered 
back to the patients directly via the intra-arterial route.  
 
A pre-infusion CT angiogram was performed, on the basis of which a decision was taken 
whether to proceed with the stem cell infusion. If appropriate, immunoselected CD34
+
 cells 
were infused via ipsilateral middle cerebral arterial cannulation (via femoral artery 
puncture), performed by an experienced interventional radiologist, with the patient under 
local anaesthesia, and with appropriate monitoring facilities (Figure 2.1, below). The 
infusion was performed slowly over 10 minutes. The standard operating procedures (SOP) 
for the bone marrow aspiration and stem cell infusion are shown in appendices 4 and 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 1 Angiographic image of intra-arterial catheter delivery of cells to M1 
segment of left middle cerebral artery 
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√ √ √ √ √ √ √ √ √ √ √ √  
 
 
A bone marrow sample will be aspirated from the iliac crests under local anaesthesia. 
The aspirate will be sent to a GMP-licensed facility for CD34
+
stem cell separation by 
immuno-selection and takes 1 – 2 days. 
Day 1 - 
2 
  √          √ √ √ 
Day 7  √ √ √ √ √  √ √ √ √ √  √ √ 
Day 14  √ √ √ √ √  √ √ √ √ √  √ √ 
Day 30  √ √ √ √ √  √ √ √ √ √  √ √ 
Day 
180 
 √ √ √ √ √  √ √ √ √ √  √ √ 
Table 2- 3  Summary of study procedures. 
 
 
2.6 DRUG PRODUCT  
The Drug Product was composed of autologous CD34
+
 cells, collected by a process of bone 
marrow aspiration from the individual patient.   
Immunoselection was carried out by a process whereby the collected cells were labelled 
with mouse anti-human CD34
+
 anti-sera attached to magnetic beads and the antibody 
labelled CD34
+
 cells attracted to a magnetic column whilst the non-labelled cells were 
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washed to waste.  The magnetic field was deactivated and the CD34
+
 cells collected.  
Sterility of the Drug Substance was assured using the standard Bact-Alert aerobic and 
anaerobic bottles by the method as supplied by the manufacturer. A summary of the Drug 
Product specification is shown in Table 2-4.  
 
Test Test Limits 
Identity  Cells identified as CD34
+
 stem cells 
Total CD34
+
 cell count Up to 1 x 10
8
  cells/10mL 
Viable CD34
+
 cell count Greater than 70% of total cell count 
pH 7.0 to 7.4 
Sterility  No growth after 7 and 14 days incubation  
Mycoplasma test No evidence of mycoplasma infection 
 
Table 2- 4  Drug Product Specification 
 
2.6.1 CD34+ Stem Cell Preparation 
Production of a CD34
+
 stem cell concentrate took place in two stages* and is briefly 
summarised below and in figure 2.1:  
 
1. Bone marrow was taken from each patient recruited into the trial, by an experienced 
haematologist. Specific blood tests were performed prior to the procedure (blood count, 
coagulation and infectious disease markers, namely Anti- HIV 1&2, HBsAg, Anti HBc, 
Anti-HCV Ab, HTLV 1 + 2 and syphilis serology).Subsequently, bone marrow was 
aspirated from the iliac crest and sent for further processing. 
 
2. The second stage of production was carried out at the Hammersmith Hospital Stem Cell 
Laboratory and involved the separation of the CD34
+
 stem cells and loading in Human 
Albumin Solution (HAS) for administration to the patient. 
 
This stage of the process was conducted under aseptic conditions.  The aspirated bone 
marrow was first washed in PBS (phosphate buffered solution), EDTA 
(Ethylenediaminetetraacetic acid) and HAS to remove any cellular debris, followed by the 
addition of a set volume of specific cell type reagent composed of CD34
+
 antibody coated 
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magnetic beads. Following mixing, the bag was aseptically connected to the CliniMACS 
machine. An automated process applied the cells to the separation column, performed a 
series of washes and finally the purified CD34
+
 cells were obtained.  
 
 
Figure 2- 2 Flow Chart of the Manufacturing Process from collection of donor 
bone marrow cells to immunoselected CD34
+
 stem cells  
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2.7 OUTCOMES 
Clinical outcome measures and neuro-imaging in the form of MRI was carried out at 
specified time points, as follows: Days 0, D1-2 (post-infusion), D7, D14, D30 and D180. 
CT imaging was acceptable if the patient was unable to tolerate MRI. Data was collected on 
symptoms and adverse events. All patients received concurrent best medical treatment. 
2.7.1 Primary endpoints  
To assess the safety and tolerability of introduction of autologous CD34
+
 bone marrow 
stromal cells into the middle cerebral artery of patients suffering from acute ischemic total 
anterior circulatory stroke or partial anterior circulatory stroke.  
 
Safety was evaluated in terms of adverse events graded according to CTC (common 
toxicity criteria) criteria and laboratory test results. All adverse events (as classified by 
ICH/GCP criteria) were graded for relationship to treatment and as expected and 
unexpected. They were reported to the stem cell group, the appropriate Ethics Committee 
and Competent Authority as required, as well as an independent safety monitoring 
committee.  
 
2.7.2 Secondary endpoints  
Clinical outcomes were assessed using 
 the Modified Rankin Score (mRS) 
 the National Institutes of Health Stroke Scale (NIHSS)  
  patients’ self reported symptoms 
 
Neuroimaging outcomes comprised qualitative assessments of T2, FLAIR, and gradient-
echo or susceptibility-weighted MRI at each time point by a consultant neuroradiologist, as 
well as estimation of lesion volume based upon T2 weighted MRI images.  
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2.8 STATISTICAL ANALYSIS 
This was an unblinded proof of concept study with an expected cohort size of up to 10. 
Differences were analysed using a paired t test where appropriate. P<0.05 was taken to 
denote statistical significance.  
 
  
55 
 
 
 
 
 
 
 
 
 
 
 
3 Clinical Results 
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Chapter Three 
Clinical Results 
 
 
3.1 RECRUITMENT 
Seventy six patients with TACS subtypes were screened between December 2007 and 
September 2011. Six patients with PACS (with NIHSS>/=8) phenotype were screened from 
August 2010 (after incorporation into the inclusion criteria) up to September 2011.  
 
Of the 82 patients screened, 5 were recruited to the study and were enrolled within 7 days 
of the event, as per pre-specified criteria.  
 
 
3.1.1 Reasons for exclusion 
A total of 66 patients were excluded from entering the study. The major reasons for 
ineligibility were: age >80 (19), significant co-morbidity/medical instability (17) and 
ipsilateral internal carotid artery occlusion or significant stenosis (13). Detailed exclusion 
criteria are listed in Table 3.1. 
 
Sixteen patients were eligible for the trial. Of these, 6 refused consent, and a further 5 were 
unable to participate due to lack of availability of (stem cell laboratory) staff. Ultimately, 5 
patients were recruited to the trial (Figure 3.1). 
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EXCLUSION CRITERIA NUMBER OF PATIENTS 
MEETING THIS CRITERIA 
Age > 80 19 
Age < 30 1 
  
Haemorrhagic Transformation 4 
Medically unwell/Palliative 17 
Recruited to IST3 Trial 1 
Hemicraniectomy 4*  
Internal Carotid Artery (ICA) 
Stenosis/Occlusion 
13 
On anticoagulation 2 
Severe CRF/on dialysis 2 
Minimal neurological deficit at recruitment 1 
Deranged Liver Function Tests 1 
  
Symptoms > 1 week 2 
  
TOTAL NOT RECRUITED 66 
 
Table 3- 1  Breakdown of how & why patients were excluded from the study 
*(One patient had ICA occlusion & hemicraniectomy) 
 
 
 
Figure 3- 1 Patient Flow Diagram 
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3.1.2 Patient Demographics 
The mean age of the recruited patients was 58 years and 60% were male. All patients 
received the immunoselected autologous CD34
+
 stem cell infusion and none of the patients 
were lost to follow-up. The mean dose of cells administered was 2.20 x 10
6
. Demographics 
of the 5 enrolled patients are documented in Table 3.2. 
 
 
 
 
 PATIENT 1 PATIENT 2 PATIENT 3 PATIENT 4 PATIENT 5 
Age 75 67 57 47 45 
Gender Male Male Male Female Female 
Stroke Subtype 
(OCSP)  
TACS TACS TACS PACS TACS 
Side of Infarct Left Right Right Left Left 
Thrombolysed? No No Yes No Yes 
Hypertension Yes Yes Yes No No 
Diabetes No No No No No 
Hypercholestero
laemia 
Yes Yes Yes Yes Yes 
Smoking No Yes No No Yes 
Atrial 
Fibrillation 
No Yes No Yes No 
Stroke aetiology undetermined cardioembolic undetermined cardioembolic undetermined 
Dose of CD34
+
 
cells delivered 
1.2 x 10
6 2.79 x 106 2.52 x 106 2.07 x 106 2.42 x 106 
Day 0 NIHSS 4 17 14 8 9 
Day 180 NIHSS 0 5 2 1 3 
Day 0 MRS 3 5 4 3 4 
Day 180 MRS 1 3 2 0 2 
 
Table 3- 2  Patient demography for the enrolled subjects 
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3.2 OUTCOMES 
3.2.1 Safety and trial conduct  
All 5 patients tolerated the procedure well, with no complications. There were no recurrent 
strokes during the follow-up period, and no post-procedure neurological deterioration. 
There were no deaths. One patient developed renal dysfunction two weeks after the 
infusion, and subsequently suffered an episode of pneumonia. These resolved, and were 
deemed to be serious adverse events as they led to a prolongation of hospital stay, but were 
not related to the intervention. 
3.2.2 Clinical outcomes 
Serial NIHSS and mRS scores are tabulated in Figures 2 and 3. All patients improved by 
Day 180 review. The median NIHSS scores were 9 (IQR=8-14) at Day 0 and 2 (IQR=1-3) 
at Day 180. Median mRS scores were 4 (IQR=3-4) at Day 0 and 2 (IQR=1-2) at Day 180.  
 
There was a significant improvement in mean NIHSS from 10.40 to 2.20 (p=0.007; 95% CI 
3.69 to 12.71) and mean mRS scores from 3.80 to 1.60 (p=0.0004; 95% CI 1.64 to 2.76) 
between Day 0 to Day 180. 
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Figure 3- 2 NIHSS scores on admission and days 0 -180 
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Figure 3- 3 mRS scores on admission and days 0-180 
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3.2.3 Radiological Outcomes 
Discussion of radiological outcomes is presented in the imaging chapter 
 
3.3 CASE REPORTS 
Detailed case reports of the 5 recruited subjects are described as follows. 
3.3.1 Subject 1 
3.3.1.1 Presenting History 
A.N, a 75 year old previously fit and well right-handed man, presented on 23.01.2008 with 
acute onset right sided weakness, facial droop and inability to speak. On arrival at St 
Mary’s Hospital, he was found to be aphasic, with right sided weakness grade 3/5, and a 
right upper motor neurone facial nerve palsy. Visual field examination revealed evidence of 
a right homonymous hemianopia. CT brain without contrast showed no evidence of 
intracranial haemorrhage, with early signs of a left middle cerebral artery (MCA) infarct. 
This clinical presentation was in keeping with a left hemisphere total anterior circulation 
(TACS) infarct, using the Oxford Community Stroke Project (OCSP) classification.  
 
Neurovascular risk factors included a history of hypertension only. Other past medical 
history included a recent history of haematuria secondary to transitional cell carcinoma of 
the bladder. This had been resected endoscopically 2 weeks previously under the care of a 
consultant urologist, with histology showing complete resection of the lesion. CT imaging 
of the abdomen and pelvis had shown no evidence of tumour progression or spread.  
 
Drug History on admission was Co-Diovane (Valsartan/Hydrochlorothiazide) 125/12.5mg 
once daily. There was no smoking history, and he was working as a property lawyer full-
time prior to admission. 
 
In view of his early presentation (within 3 hours of onset of symptoms), he was considered 
a candidate for intravenous thrombolysis, and referred immediately to the neurology team 
on-call. However, on the basis of a recent history of haematuria and surgery for a bladder 
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tumour, it was felt inappropriate to proceed. He was subsequently transferred to the stroke 
unit for his ongoing care.  
 
3.3.1.2 Neuroimaging 
Initial CT without contrast showed ill defined low attenuation changes in the corona 
radiata, in keeping with early changes of a left MCA infarct. Subsequent MRI with 
diffusion-weighted imaging confirmed an acute infarct, with reduced diffusion in the 
territory of the left MCA.  
 
CT angiography confirmed normal carotid vasculature bilaterally, with no evidence of 
intra-cranial occlusive disease.  
 
3.3.1.3 Stem Cell Treatment 
A.N was deemed appropriate for inclusion in the stem cell trial (according to the pre-
specified inclusion criteria), and was therefore approached for consent. His dysphasia had 
improved by 29.01.2008, and after consultation with the speech and language therapist, it 
was felt that he had capacity to consent. Written informed consent was obtained and the 
trial commenced on 30.01.08 (Day 0 of Trial). 
 
Bone marrow aspiration of 10mls from the right iliac crest was performed under aseptic 
conditions, by a specialist registrar in haematology (Day 0 of trial). The procedure was 
uncomplicated and well tolerated. The sealed sample was transported to the GMP approved 
stem cell laboratory and a 10ml sample of immuno-selected CD34
+
 cells was returned to St 
Mary’s Hospital the next day for autologous infusion. This was dispatched with a certificate 
of approval, based on pre-specified criteria. The total CD34
+
 cell count obtained was 1.2 x 
10
6
. The sample was stored in the haematology laboratory at 4 degrees Celsius overnight, 
for infusion the following morning.  
 
A.N underwent autologous infusion of the immunoselected CD34
+
 sample under 
angiographic guidance, by a consultant interventional radiologist. The left MCA was 
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cannulated, via femoral artery puncture, and the sample infused over 10 minutes. There 
were no immediate complications post-procedure, and the patient was transferred back to 
the ward.  
 
3.3.1.4 Follow-up 
A.N was followed-up at the pre-specified time points of Days 7, 14, 30 and 180. A full 
medical assessment including neurological examination, blood tests and ECG were 
performed at each visit. Modified Rankin Scale (mRS) and National Institute of Health 
Stroke Scale (NIHSS) scores were recorded. MRI head scan with diffusion weighted 
imaging was done at each time point.  
 
3.3.1.5 Clinical Outcome 
A.N has made steady progress since the event. His right sided weakness had resolved 
completely by Day 7 of the trial. He was aphasic on admission. This improved within 24 
hours, with a residual, moderately severe expressive dysphasia and moderate dysphagia 
(requiring naso-gastric feeding) noted by the speech and language therapist. A.N was 
transferred from the acute stroke unit at St Mary’s Hospital, to the stroke rehabilitation unit 
at Queen Square, on 21.02.08. He underwent specialist rehabilitation there, and was 
subsequently discharged on 14.03.08.  
 
On discharge, he was independently mobile. His expressive dysphasia had improved, with 
mild residual word-finding difficulties and some higher-level cognitive impairment. His 
swallow was deemed to be safe, with a normal diet. Recommendation were made that he 
was safe for discharge home, but should have supervision for going outdoors.  
 
Following discharge from hospital, A.N was seen for his final Day 180 review on 
21.07.2008. He had made ongoing progress in terms of his dysphasia and higher level 
functioning. He was back at work part-time. He was able to travel independently from work 
to St Mary’s Hospital for his appointment, requiring a train and tube journey, as well as a 
walk to the hospital from the station. His partner reported improvements in his word-
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finding difficulties, with some residual problems with his memory and retaining new 
information.  
 
3.3.1.6 Neurological Outcome Measures 
NIHSS and mRS scores are tabulated below (Figures 3.4 and 3.5). Day 0 denotes the 1
st
 
day of the trial when bone marrow aspiration was performed. MCA infusion of 
immunoselected CD34
+
 cells occurred on Day 2 (denoted by arrow). The 1
st
 post-treatment 
follow-up was on Day 7. 
 
3.3.1.7 Radiological Outcome Measures 
This is discussed in the imaging chapter 
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Figure 3- 4 Subject 1 NIHSS scores 
 
 
 
 
Figure 3- 5 Subject 1 mRS scores 
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3.3.2 Subject 2  
3.3.2.1 Presenting History 
T.A.S, a 67 year old previously fit and well right handed man, presented on 28.02.09 with 
acute onset left sided weakness, noticed after a fall in the library. On examination, he had 
evidence of weakness and hemisensory loss affecting the left side of his face, his left arm 
and left leg (UL power 1/5, LL power 2/5 proximally and 3/5 distally). Visual field 
assessment revealed evidence of a left homonymous hemianopia, as well as left sided 
neglect. He was dysarthric, and a swallow assessment revealed evidence of a moderate to 
severe dysphagia. CT brain without contrast showed a large right middle cerebral artery 
(MCA) territory infarct. The clinical picture was compatible with a right hemisphere total 
anterior circulation (TACS) infarct, using the Oxford Community Stroke Project (OCSP) 
classification. 
 
Neurovascular risk factors included a history of permanent AF, hypertension, 
hypercholesterolaemia, and a past smoking history. There was a history of alcohol 
dependence, with a previous intake of ~50units per week. Other past medical history 
included a history of mild chronic renal impairment, psoriasis and gout. He was retired and 
independent with his activities of daily living prior to admission.  
 
Drug history on admission was as follows: Aspirin 75mg once daily, Digoxin 125mcg once 
daily, Diltiazem MR 60mg twice daily, Bendroflumethazide 2.5mg once daily, Lisinopril 
30mg once daily, Atorvastatin 10mg once daily, Allopurinol 100mg once daily, Thiamine 
100mg once daily, Vitamin co B strong 1 tablet daily.  
 
T.A.S was not a candidate for thrombolysis, having presented outside the time window. He 
was admitted to the stroke unit and treated with standard best medical care.  
 
3.3.2.2 Neuroimaging 
Initial CT without contrast showed early changes within the region of the right MCA, in 
keeping with an acute large right MCA territory infarct. Subsequent MRI with diffusion-
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weighted imaging confirmed a large acute infarct of the right MCA, particularly affecting 
the right superior temporal gyrus, inferior frontal gyrus and basal ganglia and corona 
radiata. Small chronic cerebellar infarcts were also noted bilaterally.  
 
CT angiography revealed complete occlusion of the left internal carotid artery (ICA).  The 
right internal carotid artery showed no significant stenosis. There was focal narrowing of 
the right MCA noted, 8mm from the posterior communicating branch. 
 
3.3.2.3 Stem Cell Treatment 
T.A.S was deemed appropriate for inclusion in the stem cell trial (according to the pre-
specified inclusion criteria), and was therefore approached for consent. He had capacity to 
consent. Written informed consent was obtained and the trial commenced on 04.03.09 (Day 
0 of Trial). 
 
Bone marrow aspiration of 10mls from the iliac crest was performed under aseptic 
conditions, by a specialist registrar in haematology (Day 0 of trial). The procedure was 
uncomplicated and well tolerated. The sealed sample was transported to the GMP approved 
stem cell laboratory at the Hammersmith Hospital. A 13.5ml sample of immuno-selected 
CD34
+
 cells was returned to St Mary’s Hospital the next day for autologous infusion. This 
was dispatched with a certificate of approval, based on pre-specified criteria. The total 
CD34
+
 cell count obtained was 2.79 x 10
6
.  
 
T.A.S underwent autologous infusion of the immunoselected CD34
+
 sample under 
angiographic guidance, by a consultant interventional radiologist. Angiography revealed 
complete occlusion of the left internal carotid artery (unaffected side), with no significant 
stenosis of the right ICA. The right MCA was cannulated, via femoral artery puncture, and 
the sample infused over 10 minutes. There was a mild stenosis of the right MCA, and 
therefore the catheter tip was only advanced to the origin of the MCA. There were no 
immediate complications post-procedure, and the patient was transferred back to the ward. 
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3.3.2.4 Follow-up 
T.A.S was followed-up at the pre-specified time points of Days 7, 14, 30 and 180. A full 
medical assessment including neurological examination, blood tests and ECG were 
performed at each visit. Modified Rankin Scale (mRS) and National Institute of Health 
Stroke Scale (NIHSS) scores were recorded. MRI head with diffusion weighted imaging 
was done up to the day 30 review. Day 30 MRI was delayed by 4 weeks, due to ongoing 
medical complications of the stroke. Final Day 180 imaging was also delayed as he failed 
to attend a number of appointments.  
 
3.3.2.5 Clinical Outcome 
T.A.S was managed on the acute stroke unit at St Mary’s Hospital up to 12.05.09. He 
suffered a number of medical complications during his admission. He was treated for 
pneumonia and subsequently for a suspected pulmonary embolus. He had an episode of 
acute on chronic renal failure (2 weeks after the stem cell infusion-19.03.09) which was 
managed conservatively with optimisation of his fluid balance and treatment of his 
underlying sepsis. The renal function had returned to baseline at his Day 180 visit. The 
episodes of pneumonia and worsening renal failure were deemed to be Serious Adverse 
Events, as they were both associated with prolongation of hospital stay. However, the above 
complications were deemed to be Not Related to the stem cell treatment, but rather a 
consequence of the large MCA ischaemic stroke.  
 
Neurologically, T.A.S made steady progress since the event. His weakness and neglect 
improved significantly. In addition his dysphagia had resolved. T.A.S was transferred from 
the acute stroke unit at St Mary’s Hospital, to the stroke rehabilitation unit at Queen 
Square, on 12.05.09. He underwent specialist rehabilitation there, and was subsequently 
discharged to his own home on 09.07.09.  
 
He underwent multidisciplinary community rehabilitation after discharge, and made 
significant improvements. He was independently mobile with the assistance of a stick. His 
swallow was safe, and he was on a normal diet. Recommendations were made that he was 
safe for mobilising at home, but should have supervision for going outdoors.  
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T.A.S was seen for his final Day 180 review on 15.09.09. He had made ongoing progress in 
terms of his mobility and self-care. At Day 180 review, power on his left side was as 
follows: UL proximally 3/5, distally 1/5, LL proximally 4/5, distal 5/5. He was 
independently mobile with a stick, and felt steadier on his feet since the community 
physiotherapy. He used a wheelchair for outdoors mobility, though could walk short 
distances with supervision. He was independent with some of his self-care, including 
toileting, though did still require assistance from his carer for buttoning up clothes and for 
bathing/showering.  
 
3.3.2.6 Neurological Outcome Measures 
NIHSS and mRS scores are tabulated below. Day 0 denotes the 1
st
 day of the trial when 
bone marrow aspiration was performed. MCA infusion of immunoselected CD34
+
 cells 
occurred on Day 1 (denoted by arrow). The 1
st
 post-treatment follow-up was on Day 7.  
 
3.3.2.7 Radiological Outcome Measures 
This is discussed in the imaging chapter. 
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Figure 3- 6 Subject 2 NIHSS scores 
 
 
 
 
Figure 3- 7  Subject 2  mRS scores 
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3.3.3 Subject 3 
3.3.3.1 Presenting History 
M.N, a 57 year old previously fit and well man, was admitted to Charing Cross Hospital on 
12.04.2010 with left sided weakness (face, arm and leg), homonymous hemianopia, 
dysarthria, and hemineglect. The clinical presentation was in keeping with a right 
hemisphere total anterior circulation (TACS) infarct, using the Oxford Community Stroke 
Project (OCSP) classification. 
 
He had a significant PMH including, hypertension, ischaemic heart disease, 
hypercholesterolaemia, previous TIA and polycythaemia rubra vera. He was a smoker of 4 
cigarettes/day, and was an ex-heavy drinker. He worked as a cab driver prior to admission.  
 
Drug history prior to admission was as follows: Enalapril 20mg od, Amlodipine 10mg od, 
Atenolol 50mg od, Bendroflumethazide 2.5mg od, Doxazocin 16mg od, Simvastatin 40mg 
od, Aspirin 75mg od. 
 
M.N presented within 3 hours of onset of symptoms. His CT showed no contraindications 
for thrombolysis, and he was therefore thrombolysed with intravenous Alteplase on 
12.04.2010. Unfortunately, post thrombolysis, he showed no improvement, and his NIHSS 
score deteriorated from 9 to 14. CT head the next day confirmed a large right MCA infarct, 
with no evidence of haemorrhagic change. He was subsequently considered for inclusion 
into the stem cell trial. 
 
3.3.3.2 Investigations 
Baseline bloods revealed a normal full blood count, in particular normal haemoglobin and 
clotting screen. Serum cholesterol was high. 
 
Initial CT head without contrast showed early changes of a right MCA infarct. Subsequent 
MRI head with diffusion-weighted imaging confirmed an acute infarct, with reduced 
diffusion in the territory of the right MCA. 
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CT angiography confirmed normal carotid vasculature bilaterally, with no significant 
intracranial disease, apart from an M2 stenosis of the right middle cerebral artery. 
3.3.3.3 Stem Cell Treatment 
MN was deemed appropriate for inclusion in the stem cell trial (according to the pre-
specified inclusion criteria), and was therefore approached for consent. Written informed 
consent was obtained on 19.04.2010, and the trial commenced. 
 
Bone marrow aspiration of 10mls from the right iliac crest was performed under aseptic 
conditions, by a specialist registrar in haematology (Day 0 of trial). The procedure was 
uncomplicated and well tolerated. The sealed sample was transported to the GMP approved 
stem cell laboratory at the Hammersmith Hospital, by medical escort. A 13.5 ml sample of 
immuno-selected CD34
+
 cells was returned to St Mary’s Hospital the same day for 
autologous infusion. This was dispatched with a certificate of approval, based on pre-
specified criteria. The total CD34
+
 cell count obtained was2.52 x 106. 
 
MN underwent autologous infusion of the immunoselected CD34
+
 sample under 
angiographic guidance, by a consultant interventional radiologist on Day 0. The right MCA 
was cannulated, via femoral artery puncture, and the sample infused over 10minutes. There 
were no immediate complications post-procedure, and the patient was transferred back to 
the ward. 
 
3.3.3.4 Follow-up 
MN was followed-up at the pre-specified time points of Days 7, 14, 30 and 180. A full 
medical assessment including neurological examination, blood tests and ECG were 
performed at each visit. Modified Rankin Scale (mRS) and National Institute of Health 
Stroke Scale (NIHSS) scores were recorded. MRI head with diffusion weighted imaging 
was done at each time point. 
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3.3.3.5 Clinical Outcome 
M.N made steady progress since inclusion in the trial. He was transferred to his local 
hospital (West Middlesex Hospital) for ongoing rehabilitation after 2 weeks, and was 
subsequently discharged home from there, with community rehabilitation follow-up. At 6 
month review, his left sided weakness and visual field defect had completely resolved, and 
he was now mobilising independently and back at home. He had been referred for 
vocational rehabilitation, to allow him to return to work. 
 
3.3.3.6 Neurological Outcome Measures 
NIHSS and mRS scores are tabulated below. Day 0 denotes the 1st day of the trial when 
bone marrow aspiration was performed. MCA infusion of immunoselected CD34
+
 cells 
occurred on Day 0. The 1st post-treatment follow-up was on Day 7. 
 
3.3.3.7 Radiological Outcome Measures 
 
This is discussed in the imaging chapter 
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Figure 3- 8 Subject 3 NIHSS scores 
 
 
 
 
Figure 3- 9 Subject 3 mRS scores 
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3.3.4 Subject 4  
3.3.4.1 Presenting History 
J.S, a 47 year old right-handed woman, presented to Charing Cross Hospital on 13.02.2011 
with acute onset speech disturbance and right facial weakness. On admission she was found 
to be severely dysphasic, with right facial weakness and minor right arm weakness. This 
clinical presentation was in keeping with a left hemisphere partial anterior circulation 
(PACS) infarct, using the Oxford Community Stroke Project (OCSP) classification.  
 
Past medical history included a recent Right MCA infarct in January 2011 (no residual 
deficit) of unknown aetiology, and hypercholesterolaemia. She was a house-wife.  
 
Medication on admission included Aspirin 75mg once daily, Dipyridamole MR 200mg 
twice daily and Simvastatin 40mg once daily.  
 
In view of the recent ischaemic stroke, she was not a candidate for thrombolysis, however, 
she did fit the criteria for the stem cell trial, and was therefore considered for inclusion. 
 
3.3.4.2 Investigations 
Baseline bloods were within normal limits.   
 
Initial CT head scan without contrast showed early changes of a left MCA infarct, with 
subtle loss of definition of the left insular cortex. Subsequent MRI head scan with 
diffusion-weighted imaging confirmed an acute infarct, with reduced diffusion in the 
territory of the left MCA, as well as an old right MCA infarct.  
 
CT angiography confirmed normal carotid vasculature bilaterally. There was occlusion of 
the M2 branch of the left MCA, but no other intracranial occlusive disease.  
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3.3.4.3 Stem Cell Treatment 
J.S was deemed appropriate for inclusion in the stem cell trial (according to the pre-
specified inclusion criteria), and was therefore approached for consent. Due to her 
underlying dysphasia, written informed consent from the legal representative was obtained 
and the trial commenced on 16/02/2011. 
 
Bone marrow aspiration of 10mls from the right iliac crest was performed under aseptic 
conditions, by a specialist registrar in haematology (Day 0 of trial). The procedure was 
uncomplicated and well tolerated. The sealed sample was transported to the GMP approved 
stem cell laboratory at the Hammersmith Hospital, by medical escort. A 13.5ml sample of 
immuno-selected CD34
+
 cells was returned to St Mary’s Hospital the next day for 
autologous infusion. This was dispatched with a certificate of approval, based on pre-
specified criteria. The total CD34
+
 cell count obtained was 2.07 x 10
6
.  
 
J.S underwent autologous infusion of the immunoselected CD34
+
 sample under 
angiographic guidance, by a consultant interventional radiologist on 17/02/2011. The left 
MCA was cannulated, via femoral artery puncture, and the sample infused over 10 minutes. 
There were no immediate complications post-procedure, and the patient was transferred 
back to the ward. 
 
 
3.3.4.4 Follow-up 
J.S was followed-up at the pre-specified time points of Days 7, 14, 30 and 180. A full 
medical assessment including neurological examination, blood tests and ECG were 
performed at each visit. Modified Rankin Scale (mRS) and National Institute of Health 
Stroke Scale (NIHSS) scores were recorded. MRI head with diffusion weighted imaging 
was done at each time point.  
 
3.3.4.5 Clinical Outcome 
J.S made excellent progress since the event. She was discharged home after 2 weeks, with 
community speech and language therapy follow-up. At Day 180 review, she had a very 
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mild residual dysphasia, but no other focal neurological signs. She was independent and 
self-caring.  
 
During her admission, her stroke investigative work-up revealed evidence of paroxysmal 
atrial fibrillation, for which she was subsequently warfarinised. She has tolerated this well, 
and is under follow-up with the cardiologists 
 
3.3.4.6 Neurological Outcome Measures 
NIHSS and mRS scores are tabulated below. Day 0 denotes the 1
st
 day of the trial when 
bone marrow aspiration was performed. MCA infusion of immunoselected CD34
+
 cells 
occurred on Day 1 (denoted by arrow). The 1
st
 post-treatment follow-up was on Day 7.  
 
3.3.4.7 Radiological Outcome Measures 
This is discussed in the imaging chapter 
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Figure 3- 10 Subject 4 NIHSS scores 
 
 
 
Figure 3- 11 Subject 4 mRS scores 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Admission Day 0 Day 7 Day 14 Day 30 Day 180 
NIHSS Score 
0 
0.5 
1 
1.5 
2 
2.5 
3 
Admission Day 0 Day 7 Day 14 Day 30 Day 180 
Modified Rankin Scale 
80 
 
3.3.5 Subject 5 
3.3.5.1 Presenting History 
T.W, a 45 year old previously fit and well lady, presented to Charing Cross Hospital on 
11.09.2011 with right sided weakness and an inability to speak. On admission, she was 
found to be aphasic, with right (upper motor neurone) facial weakness, and right arm 
weakness (grade 3/5 distally, 5/5 proximally). Visual field examination revealed a right 
homonymous inferior quadrantanopia. This clinical presentation was in keeping with a left 
hemisphere total anterior circulation (TACS) infarct, using the Oxford Community Stroke 
Project (OCSP) classification.  
 
Past medical history included a previous stroke 6 years previously (no residual deficit) of 
unknown aetiology, heavy smoking (40-50 cigarettes/day), and possibly alcohol excess. 
She was on no regular medication. She was unemployed.  
 
T.W presented within the time window for thrombolysis, with no contraindications, and 
was therefore thrombolysed within 4 hours of the onset of her symptoms. Unfortunately, 
she failed to show any significant recovery post-thrombolysis. T.W fit the criteria for the 
stem cell trial, and was therefore considered for inclusion. 
 
3.3.5.2 Investigations 
Baseline bloods were within normal limits, apart from raised serum cholesterol.  
 
Initial CT head scan without contrast showed early changes of a left MCA infarct. 
Subsequent MRI head scan with diffusion-weighted imaging confirmed an acute infarct, 
with reduced diffusion in the territory of the left MCA.  
 
CT angiography confirmed normal calibre, but tortuous carotid vasculature bilaterally. 
There was occlusion of the distal aspect of the M1 branch of the left MCA.  
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3.3.5.3 Stem Cell Treatment 
T.W was deemed appropriate for inclusion in the stem cell trial (according to the pre-
specified inclusion criteria), and was therefore approached for consent. Due to her 
underlying dysphasia, written informed consent from the legal representative was obtained 
and the trial commenced on 14/09/2011. 
 
Bone marrow aspiration of 10mls from the right iliac crest was performed under aseptic 
conditions, by a specialist registrar in haematology (Day 0 of trial). The procedure was 
uncomplicated and well tolerated. The sealed sample was transported to the GMP approved 
stem cell laboratory at the Hammersmith Hospital, by medical escort. A 13.5ml sample of 
immuno-selected CD34
+
 cells was returned to St Mary’s Hospital the next day for 
autologous infusion. This was dispatched with a certificate of approval, based on pre-
specified criteria. The total CD34
+
 cell count obtained was 2.42 x 10
6
.  
 
T.W underwent autologous infusion of the immunoselected CD34
+
 sample under 
angiographic guidance, by a consultant interventional radiologist on 15/09/2011. The left 
MCA was cannulated, via femoral artery puncture, and the sample infused over 10 minutes. 
There were no immediate complications post-procedure, and the patient was transferred 
back to the ward.  
 
3.3.5.4 Follow-up 
T.W was followed-up at the pre-specified time points of Days 7, 14, 30 and 180. A full 
medical assessment including neurological examination, blood tests and ECG were 
performed at each visit. Modified Rankin Scale (mRS) and National Institute of Health 
Stroke Scale (NIHSS) scores were recorded. MRI head with diffusion weighted imaging 
was done at each time point.  
 
3.3.5.5 Clinical Outcome 
T.W made excellent progress since the event. Her right sided weakness and visual field 
defect completely resolved. She was discharged home after 2 weeks, with follow-up from 
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the community rehabilitation team, in particular speech and language therapy. At Day 180 
review, her dysphasia had improved, though she still had some residual word-finding 
difficulties. There were no other focal neurological signs. She was independently mobile 
and self-caring.  
 
3.3.5.6 Neurological Outcome Measures 
NIHSS and MRS scores are tabulated below. Day 0 denotes the 1
st
 day of the trial when 
bone marrow aspiration was performed. MCA infusion of immunoselected CD34
+
 cells 
occurred on Day 1 (denoted by arrow). The 1
st
 post-treatment follow-up was on Day 7.  
 
3.3.5.7 Radiological Outcome Measures 
This is discussed in the imaging chapter 
 
 
 
 
 
 
 
 
 
 
83 
 
 
 
Figure 3- 12 Subject 5 NIHSS scores 
 
 
 
Figure 3- 13 Subject 5 mRS scores 
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3.4 CONCLUSION 
In summary, 82 potentially eligible patients were assessed for recruitment into the trial, of 
which 5 were recruited. Four patients were of the TACS subtype, and one of the PACS 
subtype of ischaemic stroke. All 5 patients tolerated the stem cell treatment well. There 
were no withdrawals from the trial, and all 5 patients completed the final study follow-up at 
6 months, as per the trial protocol. There were no treatment-related serious adverse events. 
 
Clinical outcome measures of NIHSS and mRS scores (secondary outcomes) showed 
significant improvements in all five patients from Day 0 to Day 180. The mean change in 
NIHSS score was of 8.20 (95% CI 3.69 to 12.71), with a mean change in mRS of 2.20 
(95% CI 1.64 to 2.76). 
 
Radiological outcomes are discussed in detail in the following chapter. 
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4 Imaging 
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Chapter Four 
Imaging  
 
4.1 INTRODUCTION 
Imaging is a vital component of the management of acute ischaemic stroke patients. The 
role of imaging includes exclusion of haemorrhage, selection of patients for specific 
therapies (e.g. intravenous thrombolysis) and determination of possible aetiology (e.g. 
carotid stenosis). CT scanning and MRI scanning are the two modalities of choice, being 
easily available and accessible in most stroke centres.  
 
Non contrast CT is the first line imaging modality of choice in most units. It is extremely 
quick to perform, being completed in less than 1 minute using modern scanners. It can 
exclude intracerebral haemorrhage with 100% accuracy (Hankey et al; 2002). CT is also 
able to show early changes of acute ischaemia, though in this regard, MRI is a superior 
modality. MRI has superior patho-anatomical imaging properties, and the combination of 
various MR sequences provides significantly more information than plain CT. MRI 
combining T1, T2, gradient echo and FLAIR (fluid attenuated inversion recovery) 
sequences can be completed within 10 mins. In simplistic terms, T1 weighted images will 
show the brain structure; T2 weighted and FLAIR images show up brain water content; 
gradient echo (GRE) or T2* images show up old or new blood; and DWI (diffusion 
weighted imaging) images show up areas where water movement is restricted i.e. 
intracellular oedema, as seen with acute infarction (Warlow et al; 2008). DWI imaging is 
the most sensitive and specific imaging modality for detection of acute infarction, being 
positive within minutes of its occurrence. The main drawbacks of MRI include 
contraindication in the presence of a pacemaker, and issues with patient tolerance 
particularly if the patient is claustrophobic. In the context of the acutely unwell stroke 
patient, the need to lie still for several minutes in a restricted area may not be compatible 
with the patient’s condition.  
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Imaging choice for the purpose of a trial needs to be a modality which is available and 
readily accessible for serial scanning of patients. The information provided needs to be 
relevant to the outcomes of the trial. For example, in this primarily safety trial, the imaging 
choice needs to be able to reliably exclude potential complications of the stem cell 
treatment, such as new infarcts, haemorrhagic transformation, and development of other 
new lesions including tumours. Ideally, imaging evidence of efficacy of the treatment and 
ability to track cells are other important considerations when designing a phase I trial of a 
cellular therapy.  
 
For our trial, we chose MRI as our primary modality of choice in view of its superior patho-
anatomical properties, ability to provide information regarding complications, as well as its 
potential to provide evidence of treatment efficacy. MRI can also be used to provide 
information regarding tracking of cells, and this is discussed further below. In our trial, CT 
scanning instead of MRI was permissible if there were any limitations or contraindications 
to MRI use.  CT can also provide reliable information regarding potential complications of 
stem cell infusion, though is more limited in terms of the other listed benefits of MRI.  
 
4.2 CELL TRACKING 
Tracking of cells is paramount to improving our understanding of cell migration and 
mechanisms of action. With the advent of numerous clinical trials utilising stem cells, in 
vivo tracking of transplanted cells, over a period of several weeks to months, is a major 
area of need. A number of different modalities have been investigated in this context, 
though no method has yet been found to be ideal. 
 
An ideal tracking method should meet a number of basic criteria. Frangioni et al defined 8 
ideal characteristics of tracking methods for clinical trial use. These are listed below 
(Frangioni and Hajjar, 2004): 
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1. Biocompatible, safe, and nontoxic 
2. No genetic modification or perturbation to the stem cell 
3. Single-cell detection at any anatomic location 
4. Quantification of cell number 
5. Minimal or no dilution with cell division 
6. Minimal or no transfer of contrast agent to non-stem cells 
7. Non-invasive imaging in the living subject over months to years 
8. No requirement for injectable contrast agent 
 
None of the tracking methods currently available meet all of these criteria. One commonly 
employed method in pre-clinical studies is cell labelling with superparamagnetic iron oxide 
particles (SPIO), which allows the anatomical location of transplanted cells to be 
determined using MRI (Bulte et al., 2002;Hoehn et al., 2002).  Other examples of imaging 
modalities used to track labelled cells include positron emission tomography (PET), 
bioluminescence imaging (BLI), and Single-Photon Emission Computed Tomography 
(SPECT) (Lappalainen et al., 2008;Love et al., 2007).  
 
 
PET and SPECT scanning have excellent sensitivity for detecting a given cell label, though 
anatomical /spatial resolution with these techniques is suboptimal unless combined with 
another modality such as CT (Fu et al., 2011). Two radiolabel approaches are available: 1) 
direct cell labelling with a radionuclide; and 2) reporter gene-based cell labelling. The 
former option has the drawback of decay of the radiolabel signal, such that long-term 
tracking beyond a few days is not possible. Transfection of stem cells with a reporter gene 
is an alternative form of cell labelling, which allows long-term follow-up studies, as has 
been demonstrated in animal studies. Since only live cells can produce the reporter gene 
product, this technique is better at discriminating live from dead cells and, thus, can provide 
longitudinal imaging of cell survival and engraftment in vivo. In human studies, however, 
there are issues with artificially manipulating stem cells (with a reporter gene), and 
subsequent concerns regarding long-term bio-safety of such cells. Bioluminescence 
imaging is an optical imaging technique with excellent sensitivity for tracking of live cells, 
though it also requires stem cell labelling with a reporter gene (eg. luciferase), which is 
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problematic for translation to clinical studies. A further drawback is poor spatial resolution 
limiting the visualisation of deep structures, including blood vessels (Fu et al., 2011).  
 
Imaging modalities such as SPECT or PET scanning have the drawback of exposure to 
ionising radiation, requiring a trade-off between half-life of the radio-label and long-term 
exposure to ionising radiation. In addition there is the possibility of transfer of the radio-
label from stem cells to non-stem cells.  A further drawback of most of the cell labelling 
techniques currently available (unless using reporter genes) is the difficulty tracing the 
labelled cells when they divide, either due to failure of uptake of the label or presence of a 
weaker signal in the new cells. In addition, if the cell dies and is phagocytosed by 
macrophages, any signal received will only trace the movement of the macrophage 
resulting in misleading and confusing information on the movement of viable stem cells 
(McColgan et al, 2011).  
 
In the field of stem cell therapy to date, only one clinical trial of stroke patients has 
investigated the role of tracking the transplanted cells. A study of BMMNC’s labelled with 
Technetium-99m (99mTc) looked at cell homing and uptake using whole body scintigraphy 
and SPECT scanning (Barbosa da Fonseca et al., 2010). They confirmed presence of cells 
in the brain at 2 hours, as well as distribution to the liver, lungs, spleen, kidneys and 
bladder. Furthermore, preferential accumulation of radioactivity was seen in the ipsilateral 
affected hemisphere (compared to the contralateral hemisphere) in all patients at 2 hours 
post-infusion. Tracking beyond 24-48 hours was not possible, due to decay of the 
radiolabel.  
 
 
4.3 MRI TRACKING 
MRI is available for widespread use at most stroke centres, and has an excellent safety 
profile. In contrast to most of the other tracking modalities mentioned, there is no ionising 
radiation involved in its use, and it provides excellent spatial resolution. The 2 main 
contrast agents used for MRI-based tracking of cells are gadolinium, and 
superparamagnetic iron oxide particles. The former is a T1 contrast agent (i.e. generates 
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signal which can be picked up on MRI T1 sequences), and the latter a T2/T2* contrast 
agent. It is the latter which has been utilised extensively in the pre-clinical arena, due to its 
ability to track very small numbers of stem cells over protracted periods of time. Unlike 
gadolinium, iron is naturally present in the human body, and a number of studies have 
confirmed the bio-safety of SPIO cell labeling (Bulte et al., 2007).  
 
A number of different SPIO agents have been studied in animal models. We chose to 
investigate superparamagnetic nanoparticles which are used routinely for the immune-
selection of CD34
+
 cells, thus avoiding a separate cell-labelling step in our methodology.  
 
Selection of CD34
+
 cells involves a magnetic sorting method involving the use of iron-
oxide containing anti-CD34
+
 magnetic beads (as has been described in Chapter 2; section 
2.6).  In vitro data demonstrating the use of this as a cell labeling method for MRI tracking 
purposes has been shown by our research group. Our stem cell neuroimaging group 
developed a phantom model to demonstrate that CD34
+
 magnetically immunoselected cells 
(using the CliniMACS system) dispersed in agar were visible on T2*/Gradient Echo and 
SWI (Susceptibility weighted imaging) MRI (3T) sequences. SWI imaging and T2*/GRE 
sequences both detect the presence of iron products or blood, though the former method is 
significantly more sensitive. Six serial dilutions of immunoselected CD34
+
 cells 
(concentrations from 3 x 10
5
/ml to 1 x 10
7
/ml) were compared to a control tube. 
Quantitative analysis of signal intensity was performed, blinded to tube concentration and 
position of the tubes. Visual inspection showed lower signal (hypointensity) in those tubes 
with the higher concentration of cells (Figure 4.1). Signal intensity showed an inverse 
linear correlation (correlation coefficient R
2
=0.9924) with increasing concentration of cells, 
when using SWI sequences (Figure 4.2). CD34
+
 stem cells were detectable at 
concentrations of 10
5
 – 106/ml, and SWI sequences were more sensitive than T2 or 
T2*/GRE (unpublished data).  
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Figure 4- 1 CD34
+
 stem cell concentrations. Higher CD34
+
 stem cell concentrations 
(Tubes A & B) show lower SWI signal on visual inspection of the phantom model 
 
 
 
 
 
 
Figure 4- 2 SWI Signal Intensity.  
Inverse linear relationship of SWI Signal intensity (mean of slices) with CD34
+
 cell 
concentration (unpublished data). 
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In vivo data for the CliniMACS CD34
+
 cell selection methodology has been obtained  from 
a rodent model of brain injury, where it was shown to be a viable cell labeling/tracking 
method (Jendelova et al., 2005). CD34
+
 selected cells were implanted into the injured rat 
brain, and were seen on MRI (as a hypointense signal) up to 3 weeks after treatment. They 
were therefore able to demonstrate that CD34 microbead SPIO nanoparticles can be used as 
a magnetic cell label for in vivo cell visualization. Subsequent to this, a clinical trial of 
chronic spinal cord injured patients treated with autologous CD34
+
 cells (akin to our study) 
was conducted on 16 patients (10 treated; 6 controls). The treated patients received 
autologous immune-selected CD34
+
 cells (by lumbar puncture), and the controls received 
the magnetic beads without stem cells. They were able to demonstrate a hypointense signal 
on lumbar spine MRI (suggestive of signal produced by the injected stem cells) in 5 of the 
10 treated patients, at 20 and 35 days post-treatment. No such signal was seen in any of the 
control patients (Callera and de Melo, 2007).  
 
A sub-study of the recently reported STEMS2 clinical study also investigated the potential 
of MRI tracking of CD34
+
 cells labelled using iron-oxide microbeads. This randomised 
controlled clinical trial investigated the effect of G-CSF (which mobilises CD34
+
 cells into 
the peripheral circulation) in patients with subacute stroke (England et al., 2012). As part of 
their sub study, a proportion of the patients treated in the trial had 150mls of their 
peripheral blood collected for labeling with CD34
+
 antibody containing iron-oxide 
nanobeads (using the CliniMACS system). Six patients treated with G-CSF underwent this 
procedure, including re-infusion of the labeled cells on the same day. One patient 
developed a hypodensity compatible with iron deposition (and therefore possibly the 
CD34
+
 labeled cells) within their infarct that was evident on both day 10 and 90 on 
T2*/GRE scans. The hypodensity was not present at baseline, and this participant received 
the highest number of labeled CD34
+
 cells. 
 
In summary, there is now good in vitro and in vivo data to support the use of MRI as a 
tracking tool. We chose MRI as our primary imaging modality of choice, for investigating 
safety, as well as efficacy of our stem cell therapy. In addition, MRI was used for 
investigating the potential role of tracking the immuno-magnetically selected CD34
+
 cells. 
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This method makes use of an existing cell label provided by the immunoselection process, 
and avoids a separate cell labelling step. The detailed methodology is discussed below. 
 
4.4 METHODS 
4.4.1 Qualitative analysis 
All patients underwent imaging at baseline, 0-1 day post-infusion, and at the pre-specified 
follow-up time points of days 7, 14, 30 and 180.  Imaging was performed using a 1.5 or 3.0 
Tesla MRI scanner (GE/Siemens). A midline sagittal localising view, followed by serial 
axial images of the whole brain (5mm slices), using DWI (diffusion weighted imaging), T1 
and T2 weighted images, T2*/Gradient Echo (GRE) and FLAIR (fluid attenuated inversion 
recovery) sequences, were acquired.  
 
In the advent of intolerance or contra-indication to MRI, CT scanning was permissible. 
 
Neuroimaging outcomes comprised qualitative assessments of T2 weighted images, DWI, 
FLAIR, and T2*/GRE MRI at each time point by a consultant neuroradiologist. This 
included assessment of serial scans for the development of new lesions, in particular new 
infarcts, haemorrhage or tumours.  
 
4.4.2 Quantitative analysis 
Estimation of lesion volume was performed using MRICroN software  
((http://www.mccauslandcenter.sc.edu/mricro/mricron/main.html) validated by Rorden et 
al., 2007; Geva et al., 2011). The software provided an automated calculation of lesion 
volume, based on manual delineation of regions of interest on all slices of serial scans.  T2 
weighted images were used for this purpose and assessors (SB and PB) were blinded to the 
temporal order of the scans. 
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4.4.3 Tracking 
CD34
+
 cells for intra-arterial delivery were magnetically immunoselected with CliniMACS 
iron oxide-containing anti-CD34 magnetic beads, as described previously in Chapter 2. 
Imaging was performed using 3.0 Tesla MRI (GE/Siemens): Sequences performed for 
tracking the cells were T2-weighted imaging (5mm slices), T2*/GRE (5mm) and SWI 
(1.2mm). Images for this purpose were available for patients 3, 4 and 5 only, due to prior 
unavailability of a 3.0 Tesla MRI scanner.  
 
4.5 RESULTS 
4.5.1 Qualitative Analysis 
All 5 patients had acute onset MCA territory infarcts, as confirmed by MRI diffusion 
weighted imaging (Figure 4.3). 
 
Qualitative assessment of MRI (T2, FLAIR and T2*/GRE) at each follow-up time point 
showed typical evolution of cerebral infarction with no new lesions. There was no evidence 
of new infarcts, haemorrhage or tumour after stem cell delivery, in all five patients. 
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Patient 1 Patient 3Patient 2
Patient 4 Patient 5
 
 
Figure 4- 3  Baseline DWI Images. DWI images from patients 1-5. 
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4.5.1.1 Patient 1 
Figures 4.4a & b (pre-treatment) of the baseline MRI reveals an acute left MCA infarct, as 
shown by restricted diffusion on the DWI image. Figures 4.4b-f show progressive 
maturation of the infarct, with cortical laminar necrosis at Days 7, 14 and 30, and a mature 
infarct at Day 180.  
 
 
Figure 4- 4 Patient 1 Imaging 
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4.5.1.2 Patient 2 
Figure 4.5a (pre-treatment) of the baseline CT reveals an acute right MCA infarct, as shown 
by hypodensity in the right MCA territory. Figures 4.5b-e show progressive maturation of 
the infarct on MRI scanning, with cortical laminar necrosis at Days 7, 14 and 30, and a 
mature infarct at Day 180 on the final MRI.  
 
 
Figure 4- 5 Patient 2 Imaging 
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4.5.1.3 Patient 3 
Screening MRI showed a large right MCA infarct with no evidence of haemorrhagic 
change (Figure 4.6a) . Repeat MRI pre-infusion showed again an extensive right MCA 
infarct, but with some areas of signal change on SWI (susceptibility weighted imaging) 
sequences. CT head was therefore repeated pre-infusion to exclude any significant 
haemorrhage, and this showed a large right MCA infarct with no significant haemorrhagic 
change. 
 
Post stem cell infusion, serial MRI scans showed maturation of the large right MCA infarct 
with no further significant changes up to day 180. 
 
Figure 4- 6 Patient 3 Imaging 
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4.5.1.4 Patient 4 
Serial MRI scans have shown progressive maturation of a left MCA infarct with an 
associated old right MCA infarct. There were no further significant changes or new lesions 
up to day 180. 
 
 
Figure 4- 7 Patient 4 Imaging 
 
100 
 
4.5.1.5 Patient 5 
Serial MRI scans were carried out at the pre-specified time points. Baseline MR confirmed 
a large left MCA infarct with no haemorrhagic change. Follow-up scans showed 
progressive maturation of a left MCA infarct. There were no further significant changes or 
new lesions up to day 180.  
 
 
Figure 4- 8 Patient 5 Imaging 
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4.5.2 Quantitative Analysis 
Lesion volumes estimated from T2 weighted MRI scans (Figure 4.9) are listed in Table 4.1, 
and the relative changes in lesion volume over the 6 month follow-up period from CD34
+
 
cell treatment are shown in Figure 4.10.  
 
A blinded determination of lesion volume showed a reduction in lesion volume relative to 
baseline in all patients at final follow-up. There was a non-significant reduction in mean 
lesion volume (cc) from 134.24 to 96.49 (p=0.07; 95% CI -5.46 to 80.97), between Day 0 
to Day 180. Mean percentage change from baseline was 28% at 6 months follow-up. 
 
 
 
 
 
Figure 4- 9 Example of manual delineation of ROI (region of interest): MRI T2 
slice of Patient 1 (MRICroN software) 
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Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Baseline Volume (cc) 90 208 162.81 44.05 166.33 
Day 7 96.38 162.27 147.03 31.37 100.26 
Day 14 89.1 177.13 171.88 30.29 82.89 
Day 30 76.05 175.52 140.04 28 88.15 
Day 180 69.64 186.03 134.03 26 66.73 
 
 
Table 4- 1 Serial changes in infarct volume (cc) from baseline to day 180; patients 
1-5 
 
 
 
 
 
 
 
Figure 4- 10 Percentage change in infarct volume from day 0 to 180; Patients 1-5 
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4.5.3 Tracking  
Patients 3, 4 and 5 were scanned with T2 weighted imaging, Gradient Echo/T2* and SWI 
MRI sequences. 
 
Patient 3 showed hypointense signal in the right MCA territory on SWI sequences (pre and 
post-infusion) in keeping with haemorrhagic change, rather than evidence of labelled cells. 
No new signal was seen in patient 5.  
 
Patient 4 showed new hypointense signal along the distal course of the injected middle 
cerebral artery at 1 week (Figure 4.11). This was not present prior to cell infusion, and was 
not typical of haemorrhagic change.  
 
 
Figure 4- 11 Patient 4 tracking images 
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4.6 CONCLUSION 
In summary, all 5 patients underwent serial MRI scanning up to Day 180 follow-up. There 
was no evidence of new infarcts or new haemorrhagic change after the stem cell infusion, 
in any of the patients. None of the patients developed new lesions, in particular there was 
no evidence of tumour formation up to 6 months follow-up. 
 
Volumetric analysis of serial MRI images revealed reductions in infarct volume in all 5 
patients, at final Day 180 follow-up.  
 
MRI sequences performed for the purpose of tracking the infused stem cells (in the latter 3 
patients), revealed hypointensity at the distal middle cerebral artery of patient 4, in keeping 
with possible evidence of the infused CD34
+
 cells present at Day 7 follow-up.  
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Chapter Five 
General Discussion 
 
5.1 DISCUSSION 
Ischaemic stroke is a major cause of mortality and long-term disability across the globe. 
Despite advances in treatment options, there remains a pressing need for new and effective 
treatments for severe ischaemic stroke. Stem cell therapy represents a new era in potential 
neuro-regenerative treatment options. Pre-clinical studies of stem cells have shown great 
promise, though translation to the bedside is still very much in its infancy.  
 
We conducted a phase I study investigating the effects of CD34
+
 stem cells in patients with 
ischaemic stroke. This was, to our knowledge, the first clinical study in humans of immune-
selected CD34
+
 cells delivered intra-arterially to patients with acute severe ischaemic 
stroke. Pre-clinical animal models of ischaemic stroke have shown evidence of functional 
recovery with CD34
+
 cell treatment in two well-designed studies. The timing of 
transplantation in these two studies was 48 hours and 7 days post-stroke respectively 
(Taguchi et al., 2004;Shyu et al., 2006a). Improvements were seen in cognitive, behavioural 
and motor deficits, which were not seen in control animals treated with CD34 negative cells 
or saline. Both studies showed evidence of angiogenesis and subsequent neurogenesis in 
the treated animals. One of the studies was also able to demonstrate differentiation of the 
injected CD34
+
 cells into endothelial, neuronal and glial cells.  
 
Most pre-clinical studies have shown very little evidence of engraftment of significant 
numbers of transplanted cells, and therefore it is thought that the mechanism of recovery 
occurs via a trophic effect on the brain (e.g. secretion of growth factors such as VEGF) 
including recruitment of endogenous repair processes. We hypothesised that this neuro-
reparative effect would be maximal early after the ischaemic insult. On the basis of the pre-
clinical evidence, we designed a phase I clinical trial of CD34
+
 cell treatment, with 
recruitment of patients within 7 days of the onset of their symptoms. Autologous cells were 
obtained by bone marrow aspiration from the patients, followed by immune-selection of 
CD34
+
 cells at a GMP registered stem cell laboratory. Autologous cells have the benefit of 
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having none of the ethical issues associated with the use of embryonic or foetal stem cells, 
whilst also being free of any concerns regarding immune rejection. These autologous 
CD34
+
 cells were then delivered intra-arterially into the patients’ ipsilateral middle cerebral 
artery, via the trans-femoral route.  
 
We aimed to recruit 10 patients to this phase I trial. Eighty two patients were considered for 
inclusion, and ultimately, 5 patients were recruited. Our trial population included patients 
with the total anterior circulation stroke subtype (Oxford Community Stroke Project 
classification). This TACS clinical classification includes patients with the most severe type 
of ischaemic stroke, who typically have the worst outcome. Since this was a phase I trial of 
a potentially hazardous intervention, for ethical reasons we limited our treatment population 
to this subtype of patient. Furthermore, we were deliberately cautious in our specification 
of inclusion criteria (see chapter 2/section 2.4). Of the 76 TACS patients considered, only 4 
were recruited. The major reasons for exclusion were age greater than 80 years, medical 
instability and stenosis or occlusion of the ipsilateral internal carotid artery. The slow 
recruitment to this trial was a surprise, and seemed to be mainly related to the nature of the 
TACS subtype patients, in particular medical instability and arterial anatomy. To increase 
the recruitment rate of this trial, we widened the inclusion criteria to include the PACS 
subtype (and NIHSS of >/= 8), resulting in an improved screen:recruitment ratio, with one 
patient recruited out of six screened. The overall poor recruitment to this trial is a limitation 
of our study. Future study designs will need to look at patient selection carefully, in light of 
our experience. Savitz et al (2011), for example, recruited 10 patients to their trial 
investigating the acute use of BMMNCs. They used the neurological severity NIHSS score 
for defining the inclusion criteria, rather than a clinical classification score such as the 
OCSP (Oxford Community Stroke Project). Interestingly, they also had problems with 
recruitment due to complications in the most severely affected patients (with very high 
NIHSS scores). Two patients recruited to their trial deteriorated, requiring 
hemicraniectomy, prompting them to re-define their NIHSS cut-offs to a more conservative 
range. 
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In our trial all patients were recruited within 7 days of their stroke, and underwent the 
procedures of bone marrow aspiration and subsequent intra-arterial cell delivery. 
Recruitment to acute stroke trials pose a number of challenges, including the logistics of 
coordinating different personnel involved in the study. In our trial, close coordination 
between the stroke physicians, the haematologists, the stem cell laboratory and the 
interventional radiologist was imperative for successful deployment of the treatment. We 
have shown that this is feasible in the acute setting. We attempted to minimise the risks of 
treatment by performing both bone marrow aspiration (for cell acquisition) and subsequent 
cerebral angiography (for cell delivery) under local anaesthesia, rather than with general 
anaesthesia. Performing the procedure under general anaesthetic would have allowed 
acquisition of greater volumes of marrow and hence immune-selection of more cells, but 
use of a general anaesthetic (GA) would have been potentially problematic in such a severe 
subgroup of patients so early after the stroke. Consensus opinion recommends delaying 
surgery requiring a GA for at least 1 month in patients with moderately large MCA territory 
strokes (as with our patient cohort) (Blacker et al., 2004). All 5 patients recruited to this 
trial tolerated these procedures well and no complications were encountered. The 
procedures of bone marrow aspiration within 7 days of the event, and subsequent intra-
arterial infusion of immuno-selected CD34
+
 cells were shown to be both feasible and safe 
in this cohort of patients. Intra-arterial delivery poses the potential risk of micro-
embolisation (by clumping together of cells) and subsequent new infarcts. There was no 
evidence of this in our patient group.  
 
Patients were followed up to 6 months post-treatment. The primary outcome measure was 
safety and tolerability. All patients completed the study follow up protocol, and showed no 
evidence of any treatment-related serious adverse events. Furthermore, all patients showed 
improvements in their secondary outcome measure clinical scores. While this proof of 
concept study was not designed with a control group, or powered to be able to detect 
efficacy, assessment of outcome did show a trend towards functional improvement, with all 
5 patients in our study showing significant improvements in their NIHSS and mRS scores 
by 6 months follow-up. Previously, patients with TACS have been shown to have a poor 
prognosis, with 96% of such patients being dead or dependent (mRS of 3 or above) at 6 
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month follow-up (Sandercock et al.; 1991). Four of the five patients recruited were of the 
TACS subtype, and of these, three (75%) were independent at final follow-up (defined as a 
mRS of </= 2). Savitz et al (2011) treated patients within 24-72 hours post-stroke with 
intravenously delivered autologous BMMNCs; 50% of their patients were independent at 6 
month follow-up, though they were not powered to examine efficacy. Moniche et al (2012) 
treated patients with severe ischaemic stroke within 5-9 days post-event, with intra-
arterially delivered BMMNCs (also not powered to examine efficacy); 20% of their treated 
patients were independent at 6 month follow-up. Our results of 75% TACS patients (or 
80% of the total cohort) independent at final follow-up, are therefore encouraging.  
 
Neuroimaging secondary outcome measures were obtained from serial MRI scans of all 
patients up to 6 month follow-up. Quantitative analysis using serial measurements of infarct 
volume from MRI scans can provide surrogate markers of clinical improvement after 
stroke. The expected natural history of infarct size after ischaemic stroke has been reported 
by Lansberg et al (2001). They showed evidence of infarct growth in the first 72 hours, 
followed by subsequent decreases in volume, up to 30 days follow-up. Infarct growth in the 
acute period occurs largely due to associated oedema, as well as increasing ischaemic 
injury. The reductions thereafter occur due to resolution of the oedema, as well as decrease 
of the inflammatory process. Atrophy and reversal of penumbral ischaemia also likely play 
a part. Mean lesion volume at baseline in the Lansberg series was 25cc. In our series mean 
lesion volume at baseline was 134cc, with a mean percentage change in infarct volume of 
28% from baseline to 6 months. Our figures reflect a more severely affected cohort than the 
Lansberg study, with significantly larger infarct size at baseline. In our trial, reductions in 
infarct volume were seen in all 5 patients at 6 months, compared to baseline. While such 
patterns of recovery are well-recognised in the usual natural history of ischaemic strokes, 
available data tends to concentrate on patients with smaller infarcts. Our findings in a 
severely affected cohort of patients are therefore important for informing future trials of 
CD34+ cell therapy. 
 
Long term biosafety is a major concern in the field of stem cell therapies, particularly the 
potential risk of tumour formation as associated with embryonic stem cells or certain 
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immortalised stem cell lines. However, tumour formation is not an expected finding with 
this type of autologous CD34+ stem cell. Qualitative analysis of serial MR imaging found 
no evidence of tumour up to 6 months follow-up. In addition, there was no evidence of 
post-intervention stroke (ischemic or hemorrhagic) or vascular malformation. Our results 
are therefore reassuring for future studies. 
 
Tracking stem cells is an emerging area of interest in clinical trials of cellular therapies. 
This was not a primary aim of our study, though we explored the value of MRI tracking in 
patients 3, 4 and 5, once a 3.0 Tesla MRI scanner became available for clinical use. An 
existing cell label, in the form of CD34 (iron oxide-containing) antibody beads used for the 
immuno-magnetic selection process, was used. This has been shown to be a viable and safe 
tracking method in an animal model as well as in two clinical trials (Jendelova et al.; 2005, 
Callera et al.; 2007, England et al.; 2012). In our laboratory, we have demonstrated the 
feasibility of this approach in a phantom in vitro model (unpublished data). Furthermore, in 
our trial we were able to demonstrate new signal along the distal course of the injected 
middle cerebral artery at one week post-infusion, in one patient. This may represent the 
presence of injected CD34+ cells in the ipsilateral hemisphere, at that time. One major 
advantage of this tracking method is that it avoids a separate cell labelling step, as required 
with other SPIO (superparamagnetic iron oxide) labelling techniques for MRI tracking. The 
drawback of all SPIO methods including our own, however, is that that there is no way to 
differentiate between viable cells and those that have died and been phagocytosed. In 
addition, negative contrast/signal on MRI sequences, as produced by iron labels, are 
difficult to distinguish from negative signal produced by haemorrhage, which is a common 
complication in patients with severe ischaemic stroke. This is a limitation of all SPIO 
tracking methods, though the signal seen in patient 4 in our study was unusual for 
haemorrhagic change.   
 
Our trial adds to the growing body of evidence examining the use of stem cell therapy for 
ischaemic stroke in the clinical arena. To date, a number of clinical trials have been 
completed across the world (detailed discussion: chapter 1). These have used a variety of 
different types of stem cells (mesenchymal, bone marrow mononuclear cells, neuronal 
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immortalised cells), at different time points, and via different methods of delivery (Bang et 
al.; 2005, Savitz et al.; 2011, Battistella et al.; 2011, Moniche et al.; 2012, Friedrich et al.; 
2012, Kondziolka et al.; 2000,2005). The great variation in these trials means that it is 
difficult to make any meaningful comparisons between them. As such, a number of 
questions still remain unanswered. The challenges to successful translation of stem cell 
therapy include selection of the stem cell type, patient selection, timing and route of 
delivery, dosage and tracking of cells. These areas of controversy are further discussed 
below, in the context of this present clinical trial.   
 
5.2 CD34+ STEM CELL THERAPY IN STROKE PATIENTS: CHALLENGES & 
FUTURE DIRECTIONS 
5.2.1 Which cells should be used: Bone marrow mononuclear cells versus CD34+ 
cells?  
A number of different cell types have been tested in pre-clinical stroke studies; their 
relative merits and drawbacks have been discussed previously (chapter 1). Specifically, we 
decided to investigate the effects of bone marrow derived CD34
+
 cells. Both BMMNCs, as 
well as CD34
+
 selected cells have been shown to improve outcomes in pre-clinical models 
of stroke. All bone marrow derived cells are easily accessible cells which are suitable for 
autologous as well as allogeneic use. They have been widely studied in animal models of 
ischaemic diseases, including peripheral arterial disease, myocardial ischaemia, and 
cerebral ischaemia. There are now a large number of clinical trials examining the effects of 
bone marrow derived cells, particularly in the field of cardiac ischaemia (Jiang et al.; 2010).  
One outstanding question is whether CD34
+
 cells provide any benefit over and above that 
of unselected BMMNCs? This is relevant as BMMNCs are easier to obtain in larger doses, 
though CD34
+
 selected cells provide a purer cell population for therapy. BMMNCs contain 
a number of sub-populations of cells (including ~1% CD34
+
 cells), and it is not known 
which fraction contributes to the recovery seen in animal in vivo studies. It may be that the 
CD34
+
 fraction, which contains populations of both haematopoietic stem cells, as well as 
endothelial progenitor cells, is the active component.  
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There is a dearth of comparative data between unselected BMMNCs and selected CD34
+
 
cells. Of the data that is available, there are some contrasting results. One animal study of 
rat myocardial infarction showed increased potency and therapeutic efficacy of CD34
+
 cells 
when compared with unselected BMMNCs (Kawamoto et al., 2006). In contrast, the 
REGENT clinical trial of patients with acute MI and reduced left ventricular ejection 
fraction (LVEF), found similar significantly better outcomes  (in the subgroup with 
severely reduced LVEF) using either unselected BMMNCs or CD34
+
 cell treatment, as 
compared to the control group  (Tendera et al., 2009). Of interest, however, is the fact that a 
similar benefit was seen with the use of a relatively small number of selected CD34
+
 cells 
as compared to the use of 100 times higher number of non-selected BMMNC (1.78 x 10
8
 
BMMNCs vs. 1.90 x 10
6 
CD34+). Looking specifically at the stroke data, Taguchi et al 
(2004) compared CD34
+
 cells to CD34 negative cells in a rodent model of cortical stroke. 
Benefits were seen with the CD34
+
 treatment arm, which were not reproduced in the CD34 
negative group. Further data in favour of using CD34
+
 cells comes from a recently reported 
clinical trial of intra-arterially delivered BMMNCs in acute severe ischaemic stroke 
patients (Moniche et al.; 2012). They found no correlation between recovery and numbers 
of BMMNCs injected, but did see a trend towards better outcome with higher numbers of 
CD34
+
 cells injected (as present within the BMMNC infusate). We selected the CD34
+
 cell 
for further investigation, though future studies will need to consider incorporating 
comparisons between unselected BMMNCs and CD34
+
 cells, when designing trials of bone 
marrow derived cells for ischaemic stroke.   
 
5.2.2 Patient selection 
A crucial question for future clinical trials is which patients will benefit from stem cell 
therapy. On the basis of our current knowledge, the answer to this question remains 
unclear. Animal studies have shown efficacy in both ischaemic and haemorrhagic stroke 
subtypes (Chu et al.; 2004, Giraldi-Guimaraes et al.; 2009, Andres et al.; 2008). The 
pathological type and anatomical location of the stroke are important issues. The vast 
majority of pre-clinical work has focused on ischemic rather than haemorrhagic strokes 
given that this is the most predominant stroke subtype. Within the ischaemic stroke 
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subgroup, the majority of pre-clinical evidence for benefit has been obtained from animal 
models with predominantly striatal (sub-cortical) infarcts. Cortical strokes are associated 
with larger, more damaging infarcts and successful treatment of this subgroup could 
potentially achieve the best outcome for the worst affected patients. Controversy exists as 
to whether such cortical infarcts are too large to affect any repair.  However, benefit has 
been seen in a number of animal studies utilising cortical models of stroke (Hicks et al.; 
2009, Taguchi et al.; 2004, Shyu et al.; 2006a). In particular, pre-clinical evidence for the 
benefit of CD34
+
 cells was derived from the latter 2 trials, both of which utilised cortical 
models of ischaemic stroke. This formed the basis of our selection of the TACS subtype of 
patient for this particular trial given they predominantly present with large cortical infarcts.   
 
Further issues to consider when designing clinical trials are stability of patients and 
associated co-morbidities. Patients with larger strokes, such as the TACS subtype, are 
commonly medically unwell due to multiple reasons (e.g. aspiration pneumonia, cardiac 
arrhythmias), which could preclude them from entry into acute trials despite being eligible. 
In our study, a large number of patients could not be included due to their medical 
instability and multiple comorbidities, which significantly hindered recruitment.   
 
Future CD34
+
 clinical trials will need to achieve a balance between the pathological 
subtype of stroke selected for treatment and the potential benefit of treatment for the 
patient. An approach selecting patients based on the severity of the neurological deficit 
(NIHSS) in conjunction with the anatomical location of the infarct, rather than the clinical 
subtype (OCSP) is likely to be a better method of patient selection for future trials. This 
method was incorporated into our selection method after trial amendment to include the 
PACS subtype patients (with MCA territory infarct and NIHSS>=8) and resulted in a 
greatly improved screen:recruitment ratio (from 76:4 to 6:1).    
 
5.2.3 Optimum Timing for Treatment 
Preclinical studies have shown benefits of stem cell therapy in both acute and chronic 
models of stroke. Decisions regarding the ideal timing need to take into account the likely 
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mechanism of action. A neuroprotective mechanism would require acute delivery, although 
graft survival may be affected by the damaging effects of ischemia and reperfusion, 
mediated via excitotoxic neurotransmitters, free radicals and other inflammatory mediators 
(Mitsios et al., 2006). If the aim is to enhance endogenous repair mechanisms and inhibit 
neuronal apoptosis, then acute or subacute delivery would be desirable, as these processes 
occur predominantly in the first few weeks post-ischemia (Hayashi et al., 2003;Carmichael, 
2006). A neuroreparative approach aiming for direct replacement of damaged tissue with 
new neuronal circuitry (using intracerebral transplantation), would benefit from a later 
timescale, once neuroinflammation has subsided (Kelly et al., 2004). Such a strategy would 
be looking at treatment delivered weeks to months after the stroke, in keeping with ongoing 
host plasticity during that time.  
 
The ideal timing of transplantation remains unclear. Only three of the currently published 
clinical trials have looked at stem cell delivery in the acute phase. All three of these studies 
investigated the effects of autologous BMMNC’s; one at 24-72 hours post-event, given 
intravenously; the second at 3-7 days post-event, given intra-arterially; and the third at 5-9 
days, given intra-arterially (Savitz et al.; 2011, Friedrich et al.; 2012, Moniche et al.; 2012).  
They demonstrated safety and feasibility in their subjects, though in the 3rd trial, two of the 
patients suffered isolated partial seizures at 3 months.  A further five acute/subacute trials 
(treatment within 4 weeks post-event) are ongoing or yet to report, utilising different cell 
types and different methods of delivery (NCT01501773, NCT01389453, NCT01091701, 
NCT01436487, NCT01273337) (see Chapter 1, table 1-3).  
 
CD34
+
 stem cell treatment in animal studies showed evidence of increased angiogenesis 
and subsequent angiogenesis-mediated neurogenesis, with treatment at 48 hours and 7 days 
post event, respectively (Taguchi et al.; 2004, Shyu et al.; 2006a). In keeping with the pre-
clinical evidence, we were aiming to enhance such endogenous repair mechanisms, rather 
than aiming for replacement of damaged tissue. We therefore chose an early timescale 
within 7 days of the stroke, as has been discussed previously. Future CD34
+
 studies will 
need to compare different time points for delivery, including looking at the potential for 
benefit in acute (as already shown) as well as chronic stroke models. 
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5.2.4 Route of Delivery 
Decisions regarding the route of delivery need to take into account issues regarding 
practicality and safety, as well as cell type/dosage and proposed mechanism of action. 
Studies in the pre-clinical and clinical setting have used a variety of different routes of stem 
cell delivery, illustrating the point that the best delivery method remains unclear. Benefits 
have been seen using direct intra-cerebral implantation as well as systemic delivery using 
the intravenous and intra-arterial routes (Shyu et al.; 2006a, Chen et al.; 2001, Li et al.; 
2001).  
 
Intra-cerebral implantation allows direct delivery of cells to the affected site, but is invasive 
and may present issues of disrupting the underlying brain tissue. Use of a general 
anaesthetic for intra-cerebral delivery, particularly in the acute stroke patient, is 
problematic, though alternatively a local anaesthetic can be used. 
 
The intravenous route is the safest, easiest route of delivery, though there are issues 
regarding accumulation of cells in non-target organs, with only a small proportion reaching 
the brain. The size of the cells used is important in this regard. One study comparing 
intravenously delivered stem cells of different sizes, found accumulation of all stem cells 
evenly over both lung fields, with significant trapping of mesenchymal stem cells (size 13-
19μm), in comparison to BMMNCs (5- 8μm)which showed better distribution to the brain 
(Fischer et al., 2009). CD34+ cells are 7 to 15μm in size, and may therefore be expected to 
exhibit cell trapping peripherally as demonstrated with MSCs delivered via the intravenous 
route.  
 
The intra-arterial route allows more direct delivery of cells, allowing better first pass 
delivery whilst being less invasive than direct surgical implantation. One study of ischemic 
stroke in rats compared intravenous to intra-arterial delivery of embryonic stem cell-
derived neural progenitor cells. Their data showed superior cell delivery to the ischemic 
hemisphere with the intra-arterial route. Specifically, cells were found to accumulate 
primarily in non-target organs when delivered intravenously. In contrast, signal was 
detected in the ischaemic hemisphere, when cells were delivered intra-arterially 
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(Lappalainen et al., 2008). Intra-arterial delivery is typically used in the acute phase of 
stroke to take advantage of the stroke-induced upregulation of chemo-attractant pathways 
that aid in the migration of stem cells from the periphery to the brain (Borlongan et al.; 
2011). Specifically, the main postulated mechanism for homing of CD34+ cells to the brain 
involves the upregulation of stromal derived factor-1(SDF-1) within ischemic tissues of the 
brain after acute stroke. This in turn promotes CD34+ cell recruitment from the peripheral 
blood to the site of injury, via expression of the CXCR4 receptor present on the CD34+ cell 
((Kalinkovich et al., 2009) see Chapter 2, section 2.2.2). The upregulation of SDF-1 
decreases with time after the acute ischaemic insult, thus reducing the SDF-1/CXCR4 
chemoattractant pathway for homing of the CD34+ cells. On the basis of these factors, we 
chose the intra-arterial route for acute delivery of the CD34
+
 cells in our study. In the 
future, more well-designed pre-clinical trials are needed to directly compare different routes 
of delivery, using standardised criteria. These will be vital in order to allow informed 
decisions on future use of CD34
+
 stem cells in the clinical arena. 
 
5.2.5 Dosage of Cells 
The ideal dose of stem cells to deliver also remains unclear. There is a paucity of data 
examining this question. One study of BMMNC treatment in rodents with acute ischaemic 
stroke found significant benefit with infusion of 10 and 30 million cells/kg, but no benefit 
with a lower dose of 1 million cells/kg (Yang et al., 2011). Another study examining an 
immortalised allogeneic stem cell line found a dose-response effect of the cells, with 
increasing benefit with higher doses of cells (Stroemer et al.; 2009). Two clinical trials of 
NT2N cells examined dosing in a phase I and phase II trial respectively (Kondziolka et al.; 
2000, 2005). The phase I trial was able to show some (non-significant) benefit with the 
higher dose of cells, though no such dose-response trend was seen with the subsequent 
phase II trial. Such comparative data is sparse in the pre-clinical and clinical arena. These 
questions will need to be examined more closely in future trials in both pre-clinical and 
clinical settings.  
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Our study was not designed to provide dose response data. Stem cell dosage used was 
limited by the number of cells obtained via bone marrow aspiration under local anaesthetic. 
Our ethical review board limited the aspiration to a single pull of no more than 10 mls of 
bone marrow, due to concerns for patient safety and discomfort in our cohort, achieving 
CD34
+
 cell yields of 1.2 - 2.79 x 10
6
. Of note, one recently published clinical trial of 
intravenously delivered BMMNC  treatment in acute ischaemic stroke (24-72 hours post-
event) has shown that it is feasible and safe to obtain large quantities of bone marrow with 
the aid of local anaesthesia with sedation, in acute stroke patients (Savitz et al., 2011). 
These patients (n=10) underwent bone marrow harvest involving multiple aspirations 
obtained from the posterior iliac crest, to obtain volumes of 2mls/kg of bone marrow 
aspirate, yielding 7 - 10 x 10
6
 BMMNCs per kilogram body weight. Bone marrow 
aspiration was successfully completed in all patients. There were no significant 
hemodynamic or pulmonary changes during the harvest. This is an important finding in the 
context of our trial, where numbers of cells acquired were relatively small.  
 
Future trials of CD34
+
 stem cells will need to incorporate a dose-escalation design to clarify 
how much is required to achieve the desired response, and this will help further guide the 
most optimal method of acquiring the required number of autologous cells safely. Dose 
escalations can be calculated on the basis of pre-clinical data, using a weight based 
conversion. For example, the pre-clinical CD34
+
 dose used in one rodent model was 
~2x10
5
 cells (Shyu et al; 2006a), which is equivalent to ~6.6 x 10
5 
cells per kg, or a total 
cell dose of 4.6 x 10
7
 for a 70kg man.  
 
5.3 IMAGING 
The use of imaging for tracking cells is paramount to improving our understanding of stem 
cell therapy, in particular to provide further clarity regarding cell migration and 
mechanisms of action. Currently there is no ideal method of doing this, with the different 
techniques available being suboptimal for a number of reasons (as discussed in chapter 4). 
Choice of tracking modality will need to consider not only efficacy of the technique but 
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also its practicality, particularly in the context of the acutely unwell patient, who may not 
tolerate repeated and laborious imaging sessions.  
 
There is a dearth of tracking data in the clinical arena. One clinical study investigated the 
use of SPECT scanning for tracking of radio-labelled cells (Barbosa de Fonseca et al.; 
2010). Drawbacks of this approach include exposure to ionising radiation, as well as the 
potential for leakage of the radiolabel from stem cells onto non-stem cells. Decay of the 
radiolabel also limits the time window for detection of the stem cells over protracted 
periods. In our trial, we have demonstrated the potential for using MRI (3.0 T) for the 
detection of CD34+ immuno-magnetically selected stem cells. MRI tracking has the 
advantage of lack of exposure to ionising radiation. In addition, it is readily available and 
easily accessible in most comprehensive stroke centres. The drawbacks of this approach 
have already been discussed; in particular the lack of specificity for live viable cells, 
potential loss of signal after cell division, as well as  difficulty differentiating the stem cell 
signal from that produced by haemorrhagic transformation. A number of developments in 
the arena of MRI tracking are currently underway, which may allow us to overcome these 
challenges. For example, labelling of cells with a reporter gene (such as Ferritin) for MRI 
tracking, has been shown to be possible in pre-clinical studies (Naumova et al.; 2010). This 
allows tracking of only live cells whilst also guaranteeing on-going signal irrespective of 
cell division, and therefore potentially represents the future of MRI tracking techniques. 
However, genetic manipulation of cells brings with it important biosafety issues, which will 
need to be answered before such techniques can enter the clinical arena. New MRI 
techniques have also explored the potential for detecting positive contrast/signal from iron 
labels, such that there is no confusion with the negative signal produced by artefacts/blood 
products (Cunningham et al.; 2005). Furthermore, new studies have also demonstrated 
improved sensitivity of MRI allowing even single-cell detection, which is far superior to 
PET scanning, the currently most sensitive form of stem cell imaging (Shapiro et al. ;2006). 
Further developments of these exciting advances in the field of MRI tracking are eagerly 
awaited. 
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In addition to tracking cells, imaging modalities are required to evaluate the functional 
outcome of transplanted cells. Perfusion MR studies can be used to assess for 
neovascularisation, PET scanning to assess metabolic changes, diffusion-tensor imaging to 
assess fibre tract integrity, and functional MRI (fMRI) to assess neuroplasticity.  It is likely, 
therefore, that a combination of imaging modalities will eventually be required to give a 
better overall assessment of the fate of transplanted cells, in order to further the 
understanding of their mechanisms of action.  
 
There is now also growing interest in the role of imaging to help predict which patients are 
most likely to respond, and also potentially predict the therapeutic time window for 
therapy. For example, one clinical trial using functional MRI showed that patients with 
lower motor cortex activity (as determined by fMRI), were more likely to respond to 
rehabilitation therapy (Cramer et al, 2007).  Regarding the timing of therapy, Cai et al 
(2009) used PET imaging to demonstrate when the angiogenic VEGF receptor is 
upregulated (thus predicting angiogenesis). When the aim of therapy is to enhance 
endogenous repair processes, such prediction of the timing of endogenous angiogenesis 
may be helpful, to allow tying this in with the delivery of stem cells. 
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5.4 FUTURE DIRECTIONS 
As discussed, many challenges remain to the successful translation of stem cell therapies to 
the bedside. Careful planning and collaborative work need to take place in order to 
maximise the likelihood of getting a useful answer from future studies. This includes 
considerations such as incorporation of a dose escalation design, comparisons between 
different methods of delivery, as well as different time points for delivery. The Stroke 
Therapy Academic Industry Roundtable (STAIR) II meeting elucidated the important 
considerations when designing future phase II b studies. Many of these recommendations 
are particularly relevant to the field of stem cell research (Stroke Therapy Academic 
Industry Roundtable-II (STAIR-II), 2001); see figure 5.1 – important factors highlighted). 
They emphasized that ‘lack of establishing the optimal dose, duration of therapy, and time 
window may have contributed to the failure of neuroprotection trials’. Therefore refinement 
and identification of the target population is essential. In addition, narrowing selection 
criteria in phase IIb studies to target patients more likely to respond based on clinical and 
imaging characteristics may optimise the chances of detecting a biologically relevant drug 
effect (STAIR - IV recommendations) (Fisher et al., 2005).  This recommendation has to be 
balanced against the potential drawback of having such narrow selection criteria that it 
hinders adequate recruitment. Subsequent to these publications, the  Stem Cell Therapies as 
an Emerging Paradigm in Stroke (STEPS) meeting sought to develop a framework to 
specifically help guide design of future pre-clinical and clinical studies in the field of cell 
based therapies ((STEPS, 2009); Figure 5.2). These guidelines were published after the 
onset of our clinical trial. They incorporated recommendations from experts from the pre-
clinical and clinical arena and will need to be carefully borne in mind before commencing 
any future trials.  
 
Future pre-clinical studies should aim to be standardised. Cortical infarcts should be 
compared to sub-cortical striatal lesions, to delineate the ideal pathological substrate for 
CD34
+
 therapy. In addition, demographic differences, in particular differences in age and 
gender are also likely to affect how patients respond to treatment. The vast majority of 
preclinical work has been conducted on young, previously healthy, male animals. Elderly 
patients, who represent the largest subset of stroke victims, may not derive the same benefit 
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as that seen in such animal studies. In addition, different responses may be expected in the 
different genders and age groups due to variations in immune responses and potency of 
bone marrow (Liu et al., 2009; Cordeau et al., 2008; Li et al., 2009). Studies should 
therefore incorporate male and female animals, and be repeated in aged animals.  CD34
+
 
cells should be compared to unselected BMMNCs as well as placebo (saline) controls. A 
dose-escalation model should be employed. Different time points for delivery should be 
compared, as well as different methods of intravascular delivery. Such extensive pre-
clinical work is likely to require collaboration between different laboratories. Standardising 
experimental protocols is imperative, whilst keeping the use of animals to the minimum 
possible is an essential consideration in this regard.  
 
 
 
 
Figure 5- 1 STAIR II Recommendations. Important factors relevant to stem cell 
therapy are highlighted. 
 
 
STAIR II Recommendations 
 
Considerations for Designing Phase IIb Stroke Trials 
 
 Route of administration 
 Dose range 
 Duration of treatment 
 Time from stroke onset to initiation of treatment (a key variable) 
 Pharmacokinetic profile 
 Side effects and their frequency (with attention to side effect management) 
 Interactions with other commonly used medications 
 Drug distribution to the proposed site of action 
 Refinement and identification of the target population (e.g., drugs without 
preclinical evidence of activity in white matter ischemia should not be 
studied in patients with subcortical stroke or even large cortical events with 
attendant subcortical injury) 
 Obtain evidence measurement of therapeutic activity by evaluation of  
clinical and/or surrogate markers (hints of potential effectiveness) 
 
 
Stroke 
- Admission to hospital 
- Brain scan 
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Considerations for Animal and Human Testing of Cellular Therapy 
 
Mechanism of action 
 Trophic factors 
 Cell replacement 
 Local environment support 
 Other 
 
Pathological substrate 
 Ischemic versus hemorrhagic 
 Peri-infarct versus intra-infarct 
 
 
Location of pathology 
 Cortical versus subcortical 
 Brainstem 
 
 
 
Timing after stroke 
 Acute 
 Subacute, Chronic 
 
 
Figure 5- 2 STEPS Recommendations 
 
 
5.5 FUTURE CD34+ CLINICAL STUDIES 
Based on our current knowledge, a randomised controlled phase I/IIa, dose escalation trial 
examining the effects of intra-arterially delivered autologous CD34
+
 cells, in the acute 
phase of ischaemic stroke would be the next logical step. Our trial was hindered by poor 
recruitment, and future inclusion criteria will need to be carefully considered. Patients 
should be recruited on the basis of MCA territory cortical infarction, in conjunction with an 
NIHSS score of between 6-15 (based on experience from a US study investigating acute 
BMMNC use in severe ischaemic stroke patients (Savitz et al., 2011). Autologous bone 
marrow harvest can be carried out under local anaesthesia and sedation, with a maximum of 
5 aspirates and the maximum amount aspirated limited to a total of 50mls (shown to be safe 
and tolerable in two trials of acute BMMNCs in ischaemic stroke (Moniche et al., 
2012;Friedrich et al., 2012). The trial should have a dose escalation design, and aim to 
recruit 30 patients (and 15 controls; 2:1 randomisation); such that successive groups of 10 
patients will receive ascending doses of autologous adult CD34
+
 cells at the following 
doses: 5x10
4
 cells per kg, 1x10
5
 cells per kg, and 6x10
5
 cells per kg. The dose escalations 
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are calculated on the basis of pre-clinical data, on a weight conversion basis. The rodent 
dose of ~2x10
5
 CD34
+
 cells (Shyu et al; 2006a), is equivalent to ~6.6 x 10
5 
cells per kg, or a 
total cell dose of 4.6 x 10
7
 for a 70kg man. This would be primarily a safety study, and we 
have therefore chosen lower dose equivalents for the 1
st
 and 2
nd
 batch of patients. If no 
toxicity is observed at the starting dose, we would proceed to the next dose escalation. 
Patients should be followed-up to 6 months, with serial MR imaging. In addition functional 
MRI (to investigate cerebral plasticity) and FDG-PET (to monitor metabolic activity) 
scanning at baseline, 3 months and 6 months, would add invaluable further information (in 
those patients able to tolerate this). It is clear that recruitment to acute trials can be 
problematic, and therefore a multi-centre design should be planned in order to achieve 
desired numbers of patients. 
 
Well-designed preclinical and clinical studies will be imperative in the quest for translation 
of stem cell therapy to the bedside. We will need to collaborate with other groups in order 
to make this possible, and open and honest reporting of both positive and negative results 
from trials will be essential in this regard.  
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5.6 CONCLUSION 
In summary, this is the first study in humans demonstrating that direct intra-arterial 
infusion of autologous CD34
+
 selected cells in patients with acute (within 7 days of stroke 
onset) severe ischemic stroke is safe and feasible. All patients tolerated the procedures of 
bone marrow aspiration and intra-arterial delivery of cells, with no immediate 
complications, and no treatment related serious adverse events up to 6 months follow-up. 
All patients showed improvements in clinical and functional scores (NIHSS and mRS) up 
to 6 months follow-up, though this study was not powered to examine efficacy. Despite this 
cohort representing a severe subset of ischaemic stroke patients, eighty per cent were 
independent at final follow-up. Our study was hindered by slow recruitment due to the 
severity of the subtype of patients included. This will be an important consideration in the 
future design of trials examining CD34
+
 cells in acute ischaemic stroke.  
 
Stroke remains a major cause of death and disability across the world. The advent of stem 
cell therapy is an exciting development for the treatment of this highly prevalent condition. 
Successful translation of research will depend on close future collaboration between 
different centres to develop a co-ordinated approach to clarify the remaining areas of 
uncertainty.  The results and lessons learnt from our trial will help pave the way for future 
developments in this field and raise the hope for the establishment of stem cell therapy in 
the management of stroke.  
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APPENDIX 1: PATIENT INFORMATION SHEET 
 
Patient Information Sheet 
 
 
 
You are being invited to take part in a research study. 
Before you decide it is important for you to understand 
why the research is being done and what it will involve. 
Please take time to read the following information 
carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like 
more information. Take time to decide whether or not 
you wish to take part. 
 
If you decide to take part, please let us know 
beforehand if you have been involved in any other 
study during the last year.  If you decide not to take 
part your treatment will not be affected by your 
decision.  You are free to withdraw at any time 
without explanation and your subsequent 
treatment will not be affected. 
 
 
Thank you for reading this. 
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Purpose and Background 
The doctors involved in your care have told you that you have had a major stroke.  
We would like you to consider joining a clinical research trial to discover whether it 
is safe to administer a new treatment for stroke. This involves using particular cells 
taken from your own body (stem cells), which are then specially prepared and 
injected back into you. The study will last for six months. If you agree to enter the 
study you will need to give your consent before any of these procedures are 
carried out.   
 
 
What are the possible benefits of taking part? 
We do not know what to expect from the treatment as this study has never been 
undertaken before and we do not know if there will be any improvement in your 
brain function.  The main purpose of the study is to determine the safety of giving 
stem cells to stroke patients. The information that we get from this study may 
help to improve the treatment of future patients. 
 
 
 
Treatment plan 
 
Day 0 You will be examined by the research doctor and have some blood 
tests.  You will also have a scan of your brain.  A sample of bone 
marrow will be taken from the pelvis (see diagram).  The sample will 
then be sent to the laboratory to separate out the stem cells. 
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Day 2 or 3 Once the stem cells are ready, they will be injected back into you. 
You will be given a mild sedative beforehand to make it more 
comfortable for you.  The radiologist will insert a catheter (a long, thin 
tube) into your groin and thread it up to the correct artery in the brain 
before injecting the stem cells.  Before returning to the ward, you will 
have another brain scan to monitor the cells as they settle in the 
brain.  After this you will be able to rest in the ward. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On days 7, 14, 30 and 180, you will have further brain scans to see where the 
stem cells are and how they are growing, as well as a physical 
examination and blood tests. 
 
We are attaching a chart which may help lay out the study plan more clearly. 
 
What are the side effects or risks of any treatment received when taking 
part? 
This study may involve side effects.  Please read the following section carefully, 
which details the possible risks of the procedures you will undergo. 
 
 
Possible side effects from bone marrow sampling  
There is likely to be some discomfort during this procedure. However this is kept to 
a minimum by the use of a local anaesthetic. There may also be dull soreness for a 
day or two but you will have pain relief if needed. Significant complications are 
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very unusual but can include bleeding, infection, and prolonged pain, all of which 
will be treated if they occur. 
 
Possible side effects of sedation 
There may be some drowsiness, weakness and clumsiness for a day or two after 
the procedure.  Rarely, more serious complications may occur such as breathing 
problems, which will be dealt with instantly.  
 
Possible side effects of the stem cell injection 
There may be complications when the catheter is inserted into your body to inject 
the stem cells.  This could cause interruption of blood to important organs, and 
may even lead to your death.  Infections might be introduced when the stem cells 
are given.  This is very unlikely, but if it occurs we will give you any treatment you 
might need. 
 
Possible side effects of blood sampling and cannula placements 
You may experience bleeding from the site of blood tests, or points of entry of the 
catheters inserted for the blood tests and the injection of stem cells.  If this occurs 
then we will give you treatment to remedy the situation. 
 
 
Exposure to Radiation 
Taking part in this study will mean that you will have a 6 special scans called CT 
scans in six months.  The exposure to this amount of radiation is equivalent to 
approximately 28 months of natural background radiation in the UK. 
 
 
New findings 
Sometimes during the course of a research study new information becomes 
available about the treatment that is being studied.  If this happens, your research 
doctor will tell you about it and discuss with you whether you want to continue in 
the study.   
 
What happens when the study stops? 
It is important for you to know that this treatment will not be available once the 
study stops.  Your doctor will advise you on any further treatments. 
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Confidentiality 
The results of all study tests will be discussed with you and your own doctor.  Your 
medical records will be considered confidential. If you decide to take part in the 
study your GP will be notified. 
 
 
Indemnity 
If you are harmed by taking part in this study you will be compensated through 
Imperial College School of Medicine’s “No Fault” compensation scheme. If you are 
harmed due to someone’s negligence then you may have grounds for a legal 
action but you may have to pay for it.  Regardless of this, if you have any concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, the normal NHS complaints mechanisms are available to you. 
 
Results of the study 
We hope to publish the study results in medical journals and present the data at 
medical meetings.  You will not be identified in any publications about the study.  
If you wish to read any of the publications about the study you should ask your 
doctor at the next clinic visit to give you a copy. 
 
Organisation and funding of the study 
The Departments of Surgical Oncology and Technology, Neurology Haematology, 
Imaging and Histopathology, are joint organisers of this project.   
 
Further information 
If you have any further questions, please contact Dr Chataway at St Mary’s 
Hospital on the following telephone number: 0207 886 6889 or ask one of the 
nurses on the ward to contact the stroke research team. 
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Stroke 
- Admission to hospital 
- Brain scanInvitation to 
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APPENDIX 2: PICTORIAL PATIENT INFORMATION SHEET 
 
 
Patient Information Leaflet 
 
 
 
You are being invited to take part in a research study. 
Before you decide it is important for you to understand 
why the research is being done and what it will involve. 
Please take time to read the following information 
carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like 
more information. Take time to decide whether or not 
you wish to take part. 
 
If you decide to take part, please let us know 
beforehand if you have been involved in any other 
study during the last year.  If you decide not to take 
part your treatment will not be affected by your 
decision.  You are free to withdraw at any time 
without explanation and your subsequent 
treatment will not be affected. 
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The doctors involved in your care have told you that 
you have had a major stroke.  We would like you to 
consider joining a clinical research trial to discover 
whether it is safe to administer a new treatment for 
stroke.  
 
This involves using particular cells taken from your own 
body (stem cells), which are then specially prepared 
and injected back into you. The study will last for six 
months. If you agree to enter the study you will need to 
give your consent before any of these procedures are 
carried out. 
 
The research doctor will talk you through the study 
using the flowchart and diagrams on the next pages.   
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What happens when I have a stroke? 
 
 
 
 
 
 
 
 
Removal of bone marrow stem cells 
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Injection of stem cells into the brain: 
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APPENDIX 3: LEGAL REPRESENTATIVE INFORMATION SHEET 
 
 
Legal Representative Information Sheet 
 
 
 
Your relative is being invited to take part in a research 
study. Before you decide it is important for you to 
understand why the research is being done and what it 
will involve. Please take time to read the following 
information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if 
you would like more information. Take time to decide 
whether or not you wish your relative to take part. 
 
If you decide that you wish your relative to take part, 
please let us know beforehand if they have been 
involved in any other study during the last year.   Your 
relative’s treatment will not be affected by your 
decision.  Your relative is free to withdraw at any 
time without explanation and their subsequent 
treatment will not be affected. 
 
 
Thank you for reading this. 
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Purpose and Background 
The doctors involved in your care have told you that your relative has had a major 
stroke.  We would like you to consider your relative joining a clinical research trial 
to discover whether it is safe to administer a new treatment for stroke. This 
involves using particular cells taken from their own body (stem cells), which are 
then specially prepared and injected back into them. The study will last for six 
months. If you agree for your relative to enter the study you will need to give your 
consent before any of these procedures are carried out.   
 
 
What are the possible benefits of taking part? 
We do not know what to expect from the treatment as this study has never been 
undertaken before and we do not know if there will be any improvement in their 
brain function.  The main purpose of the study is to determine the safety of giving 
stem cells to stroke patients. The information that we get from this study may 
help to improve the treatment of future patients. 
 
 
Treatment plan 
 
Day 0 Your relative will be examined by the research doctor and have some 
blood tests.  They will also have a scan of their brain.  A sample of 
bone marrow will be taken from the pelvis (see diagram).  The 
sample will then be sent to the laboratory to separate out the stem 
cells. 
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Day 2 or 3 Once the stem cells are ready, they will be injected back into your 
relative. They will be given a mild sedative beforehand to make it 
more comfortable for them.  The radiologist will insert a catheter (a 
long, thin tube) into their groin and thread it up to the correct artery in 
the brain before injecting the stem cells.  Before returning to the 
ward, they will have another brain scan to monitor the cells as they 
settle in the brain.  After this they will be able to rest in the ward. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On days 7, 14, 30 and 180, they will have further brain scans to see where the 
stem cells are and how they are growing, as well as a physical 
examination and blood tests. 
 
We are attaching a chart which may help lay out the study plan more clearly. 
 
 
What are the side effects or risks of any treatment received when taking 
part? 
This study may involve side effects.  Please read the following section carefully, 
which details the possible risks of the procedures they will undergo. 
 
 
Possible side effects from bone marrow sampling 
There is likely to be some discomfort during this procedure. However this is kept to 
a minimum by the use of a local anaesthetic. There may also be dull soreness for a 
day or two but they will have pain relief if needed. Significant complications are 
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very unusual but can include bleeding, infection, and prolonged pain, all of which 
will be treated if they occur. 
 
 
 
Possible side effects of sedation 
There may be some drowsiness, weakness and clumsiness for a day or two after 
the procedure.  Rarely, more serious complications may occur such as breathing 
problems, which will be dealt with instantly.  
 
 
Possible side effects of the stem cell injection 
There may be complications when the catheter is inserted into their body to inject 
the stem cells.  This could cause interruption of blood to important organs, and 
may even lead to their death.  Infections might be introduced when the stem cells 
are given.  This is very unlikely, but if it occurs we will give them any treatment they 
might need. 
 
 
Possible side effects of blood sampling and cannula placements 
They may experience bleeding from the site of blood tests, or points of entry of the 
catheters inserted for the blood tests and the injection of stem cells.  If this occurs 
then we will give them treatment to remedy the situation. 
 
 
Exposure to Radiation 
Taking part in this study will mean that they will have a 6 special scans called CT 
scans in six months.  The exposure to this amount of radiation is equivalent to 
approximately 28 months of natural background radiation in the UK. 
 
 
New findings 
Sometimes during the course of a research study new information becomes 
available about the treatment that is being studied.  If this happens, your research 
doctor will tell you and your relative about it and discuss with you both whether you 
want to continue in the study.   
 
What happens when the study stops? 
It is important for you to know that this treatment will not be available once the 
study stops.  Your doctor will advise you and your relative on any further 
treatments. 
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Confidentiality 
The results of all study tests will be discussed with you and your relative.  Their 
medical records will be considered confidential. If you decide that your relative can 
take part in the study their GP will be notified. 
 
 
Indemnity 
If your relative is harmed by taking part in this study they will be compensated 
through Imperial College School of Medicine’s “No Fault” compensation scheme. If 
they are harmed due to someone’s negligence then they may have grounds for a 
legal action but they may have to pay for it.  Regardless of this, if you have any 
concerns about any aspect of the way you or your relative have been approached 
or treated during the course of this study, the normal NHS complaints mechanisms 
are available to you. 
 
 
Results of the study 
We hope to publish the study results in medical journals and present the data at 
medical meetings.  Your relative will not be identified in any publications about 
the study.  If you or your relative wish to read any of the publications about the 
study they should ask your doctor at the next clinic visit to give them a copy. 
 
 
Organisation and funding of the study 
The Departments of Surgical Oncology and Technology, Neurology Haematology, 
Imaging and Histopathology, are joint organisers of this project.   
 
 
Further information 
If you have any further questions, please contact Dr Chataway at St Mary’s 
Hospital on the following telephone number: 0207 886 6889 or ask one of the 
nurses on the ward to contact the stroke research team. 
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APPENDIX 4: STANDARD OPERATING PROCEDURE FOR BONE 
MARROW ASPIRATION & COLLECTION 
 
Imperial College Healthcare NHS Trust 
Womens’ & Childrens’ Clinical Programme  (Paediatric Haematology & BMT) 
Quality Management Policy and Procedures 
 
Purpose: The purpose of this SOP is to ensure a safe and effective aspiration of 
bone marrow for the Imperial College sponsored trial HHSC/003. 
Scope: The scope of this SOP covers the procedure for bone marrow aspiration. 
 
Departmental Responsibility: Quality Date Effective: Pop by QA Manager 
Author: Soma Banerjee   Review Date: Pop by QA Manager 
Document Control 
The Master Copy of the Quality Manual and Standard Operating Procedures (SOP’s) will 
be filed in the Quality Management Office. 
Controlled copies are numbered and stamped or water marked “Controlled Copy” in red 
ink. Any copies without this red stamp are uncontrolled and should be destroyed. 
Electronic copy will be filed within a read only folder on the Trust shared network. 
 
If this SOP appears inadequate or outdated it is the responsibility of all staff to bring this to 
the attention of their Supervisor immediately. 
 
Training Record  
The training record for this SOP is filed with the master copy of the SOP in the Quality 
Management Office. 
Security Statement 
This SOP is the intellectual property of the BMT Unit within the Department of Paediatrics 
(Haematology & BMT) at the St. Mary’s NHS Trust and as such, must not be circulated 
outside of the Trust without written approval from the Quality Assurance 
Manager/Programme Director  
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1.0 Personnel & Responsibilities 
 
The clinical research fellow and Principal Investigator for the St Mary’s site will be 
responsible for: 
 
- obtaining informed consent from the patient or their representative in accordance with 
the Human Tissue Act 2004 and Human Tissue Authority requirements (example forms 
- appendices 2, 3 & 4)   
- liaising with the haematology team (Paediatric BMT unit and JGCCT). 
- delivery of the bone marrow aspirate from St Mary’s to the JGCCT Imperial College 
Healthcare NHS Trust,  Hammersmith campus  
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- Report any incidents involved in the procurement/collection  of aspirate and 
communicate according to  Trust and HTA procedures. 
 
The bone marrow aspiration will be carried out by trained personnel. 
 
The research team and patient’s medical team will be responsible for the ongoing 
assessment of the patient post-bone marrow aspiration. 
 
Overall responsibility will be with the Principal Investigator for the site and the trial 
Chief Investigator. 
 
2.0 Background  
 
The use of haematopoietic stem cells (HSCs) for bone marrow transplantation 
is well established, and the therapeutic potential of HSCs in the regeneration of 
other non-haematopoietic tissue such as heart and skeletal muscle has also 
been explored.  There is increasing evidence that HSCs can improve 
neurological function in rodent models of ischaemic stroke, particularly when 
the cells are targeted to the area of damage, hence the rationale for this 
particular trial.  Further evidence is detailed in the Trial Protocol. 
 
Project HHSC/003 (A phase I/II safety and tolerability study following the autologous 
infusion of CD34+ selected haematopoetic cells into patients with acute total anterior 
circulation ischaemi stroke). 
 
Although BM immunoselection and tissue release is carried out under a MHRA IMP 
manufacturer’s authorisation tissue the procurement is within the scope of JGCCT of 
Human Tissue Authority license 11118. This process may be subject to audit for 
compliance by the Qualified Person and/or Designated Individual or any of the relevant 
Regulatory Agencies including the MHRA Clinical Trials office.  
 
As BM aspirates for human use will be procured under the JGCCT HTA license the 
activity will be reported on an annual basis, by the DI, to the HTA. 
 
3.0 Definitions 
 
BM = Bone Marrow 
SOP = Standard Operating Procedure 
HSC = Haematopoietic Stem Cell 
ACD = Acid Citrate Dextrose 
SAE = Serious Adverse Event 
HTA = Human Tissue Authority  
DI = Designated Individual 
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QP = Qualified Person 
CRF = Case report form 
 
4.0 Health & Safety 
A detailed risk assessment for the patient is given in the current Trial Protocol ..   
 
.Appropriate safety procedures will be followed: 
 
- Wearing of appropriate protective clothing (e.g. apron, gloves etc.), is 
essential 
- Disposal of all used needles and other sharp objects immediately into an 
approved sharps container.  
 
All staff will follow Imperial College NHS Trust Health and Safety and Infection control 
procedures. 
 
5.0 Equipment/Documentation 
 
5.1 Equipment 
 
Equipment for the procedure will be provided by the research team: 
 
-  Sterile gloves  
-     Sterile protective gown   
-  Antiseptic 
- Sticking plasters 
- Sterile dressings  
- 5 ml 2% Lidocaine  
- 10 and 20mL  syringes  
- Gauge 19 and 23 needles  
- ACD anticoagulant 
- Disposable bone marrow aspiration needles  
 
5.2 Documentation 
 
The documentation provided relating to the procedure will be: 
 
- signed informed consent form 
- consumables log sheet (see Appendix 1) 
- Trial CRF 
- SAE report (if required) 
 
6.0 Procedure  
 
6.1 Scheduling the Bone Marrow Aspiration 
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Before obtaining consent and scheduling the procedure the JGCCT must be contacted 
ASAP by the Clinical Research Fellow to determine that the facility has the operational 
capacity to undertake a BM immmunoselection and facilitate QP tissue release. Once 
the procedure is confirmed a processing request form (JGCCT-FRM-003) is completed 
and FAXED to the JGCCT. The JGCCT will fax back acknowledgement of receipt. 
Before scheduling the patient for a bone marrow aspiration the patient’s case history 
must be recorded and accessed to appropriateness. The clinical research fellow will be 
responsible for contacting the haematology team and providing as much advance 
notice as possible.  The bone marrow aspiration should be done as early in the day as 
possible in order to allow adequate time for laboratory processing and 
immunoselection. 
 
6.2 Infectious disease marker testing 
 
Tests for infectious disease markers must be carried out in accordance with HTA 
requirements (Commission Directive 2006/17/EC implementing Directive 2004/23/EC 
of the European Parliament and Council as regards certain technical requirements for 
the donation, procurement and testing of human tissues and cells) and made available 
to the JGCCT ASAP and ideally prior to processing, Samples should be taken as soon 
as the procedure has been agreed in principle with the JGCCT and consent has been 
obtained. 
6.3 Location 
 
The procedure will be performed on the ward (Grafton Stroke Unit).  
 
6.4 Bone Marrow Aspiration 
 
Signed informed consent will be obtained prior to commencing the procedure and 
following blood infection mark tests being performed (blood counts, coagulation and 
infectious disease markers 
 
The aspirate will be performed under aseptic conditions.  The required equipment will 
be assembled, as detailed above (5.1). The sternal guard will be removed from the 
bone marrow aspiration needle.  
 
The site of aspiration will be the posterior iliac crest. The patient will be placed in the 
lateral decubitus position, with their knees flexed and a pillow under their head.  
 
2-5mls of 2% lidocaine will be infiltrated into the skin, subcutaneous tissues and 
periosteum. Once the area is anaesthetised, the bone marrow aspiration needle will be 
slowly advanced to allow penetration of the cortex, and entry of the marrow cavity. The 
needle can penetrate up to 1cm beyond the surface of the bone.  
 
Once the needle is in place, the obturator will be unlocked and removed. The aspirate 
will then be collected into a 20ml syringe, preloaded with anticoagulant.  The volume of 
anticoagulant has been calculated as 1.4 mL ACD per 10mL aspirate. 
 
The volume of marrow is limited to 10mLs in one single pull.  If the patient is in pain or 
is distressed, the procedure will be abandoned.   
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On completion of the procedure, the aspiration needle will be removed. Sterile gauze 
will be placed over the aspiration site, and firm pressure applied for 1-2 minutes. A 
sterile dressing will be placed over the area. The patient will then be placed in the 
supine position, and advised to remain there for 20 minutes.   
 
Following the aspiration, the syringe will be immediately capped off  
 
The consumables log is completed for returning to the JGCCT. 
 
6.5 Sample labelling and transport to JGCCT 
 
The BM sample and documentation (copy of informed consent, consumables log, 
transport log and supply of patient addressograph labels) is transported to the JGCCT. 
In accordance with PaedBMTU-COL-010 Clinical Harvests: Labelling and Transport of 
Cells to SCI Laboratory  
 
6.6 SAE Reporting 
 
All SAEs will be recorded in the approved SAE form, and reported immediately to the 
research team, appropriate ethics committee, Designated Individual, Qualified Person, 
and Quality Manger/BMT Programme Director, MHRA and the data monitoring 
committee for the trial. 
 
6.7 Deviation from SOP 
 
Any deviations from this SOP must be documented and approved according to SOP 
PaedBMTU-QMP-006. 
 
7.0 Training and Competency Assessment 
 
Type of Training New operatives will be trained by haematologists: 
1. Observing at least five procedurers 
2. Performing two procedures under supervision  
3. read and understand SOP sections re: documentation 
and transport 
Method of competency 
assessment for “procedure” 
Opinion of trainers 
 
List Staff required for Training 
and Competency Assessment 
Research team, as well as the haematology SpRs who will be 
performing the procedure. 
 
Who is to perform this training 1. BM aspirate This SOP is required reading for the research 
team, as well as the haematology SpRs who will be 
performing the procedure. 
2. documentation and transport – DI and QP 
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Evidence Log of 
Training/Competency 
Assessment 
Complete the Record Training & Comprehension 
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Appendix 1: Consumables Log Sheet 
 
St Mary’s Hospital 
 
Staff present: 
 
Date: 
 
Time: 
 
Patient Name: 
Date of Birth: 
Hospital Number: 
Trial Number: 
 
Consumables Used: 
 
Item 
 
Lot no. Expiry Date Cost 
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Appendix 2 – Condensed Patient Consent form. 
 
 
 
Protocol : HHSC/003      Patient Consent Form 
 
 
Patients Initials     Screening Number  
 
 
Stem Cell Therapy for Total Anterior Circulation Ischaemic 
Stroke 
 
1. Consent for participation in clinical trial 
(please initial boxes if they apply to you) 
 
 
I, _____________________________________ (name of patient) 
  
of, __________________________________________________ (address)                                                
 
confirm that I have read and understood the information sheet, for the above study and 
 the nature, purpose and possible consequences have been described to me. 
 
 
I have been given time to consider the trial and all my questions have been answered. 
 
 
I understand that I may withdraw my consent at any time, without giving  
a reason, and without my medical care or legal rights being affected. 
 
I understand that sections of any of my medical notes may be looked at  
by responsible individuals from regulatory authorities where it is relevant  
to my taking part in research. I give permission for these individuals to  
have access to my records. 
 
I understand that information held by the NHS and records maintained  
by the General Register/Office may be used to keep in touch with me and  
follow up my health status. I give permission for the study staff to contact  
my general practitioner with details about this study. 
 
I ___________________________(patient’s name) consent to participate  
in this research study.  
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2. Consent for Bone Marrow Aspiration 
 
To be read by the patient prior to agreeing to the process of Bone Marrow Aspiration. 
 
You will shortly undergo the process of bone marrow aspiration during which cells will be removed 
from your bone marrow and sent for separation of different cell types.  The selected cells are to be 
re-infused into you 2 to 3 days later, as part of the clinical trial that you will be asked to participate 
in.   
 
I _______________________ (patient’s name) agree to the collection of  
specified blood cells by the process of bone marrow aspiration and cell  
separation as part of clinical trial HHSC/003 
 
3. Consent for Immunoselection and Possible Discard of Stem Cells 
 
You will soon undergo a stem cell collection procedure from your bone marrow. This part is to 
record your consent to the testing, storage and possible discard of excessive stem cells. 
 
I agree to my blood being tested for infections such as Hepatitis, Syphilis and  
AIDS. If any of these tests are positive I understand that I will be informed  
and further tests, counselling, and clinical follow-up will be arranged as necessary. 
 
 
I agree that any expanded stem cells in excess of the numbers required for  
re-infusion may either be used for laboratory research only or destroyed by  
incineration. 
 
 
I give my permission for my personal information (Initials, hospital number and  
clinical code number) to be held on the National Blood Service database and for  
NBS staff to share this information with other healthcare professionals. 
 
4.  Signatures 
 
I confirm that I have read and understood the above information and give my consent to 
parts 1, 2, and 3. 
 
Name of Patient    ………………………………………………. 
 
Signature    ………………………………………………. 
 
Date     ………………………………………………. 
 
Name of person taking consent ………………………………………………. 
 
Position    ………………………………………………. 
 
Signature    ………………………………………………. 
 
Date     ………………………………………………. 
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Witness    ………………………………………………. 
 
Position/Relationship to patient ………………………………………………. 
 
Signature    ………………………………………………. 
 
Date     ………………………………………………. 
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Appendix 3 – Condensed Patient Witness Verbal Consent form. 
 
 
Protocol : HHSC/003       Patient Consent Form 
       (Witnessed verbal consent) 
 
 
Patients Initials     Screening Number  
 
 
Stem Cell Therapy for Total Anterior Circulation Ischaemic 
Stroke 
 
1. Consent for participation in clinical trial 
(please tick boxes once the patient has understood each part) 
 
 
I, _____________________________________ (name of patient) 
  
of, __________________________________________________ (address)                                                
 
confirm that I have understood the information sheet for the above study and the  
nature, purpose and possible consequences have been described to me. 
 
I have been given time to consider the trial and all my questions have been answered. 
 
 
I understand that I may withdraw my consent at any time, without giving  
a reason, and without my medical care or legal rights being affected. 
 
I understand that sections of any of my medical notes may be looked at  
by responsible individuals from regulatory authorities where it is relevant  
to my taking part in research. I give permission for these individuals to  
have access to my records. 
 
I understand that information held by the NHS and records maintained  
by the General Register/Office may be used to keep in touch with me  
and follow up my health status. I give permission for the study staff  
to contact my general practitioner with details about this study. 
 
 
I ___________________________(patient’s name) consent to  
participate in this research study.  
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2. Consent for Bone Marrow Aspiration 
 
To be understood by the patient prior to agreeing to the process of Bone Marrow Aspiration. 
 
You will shortly undergo the process of bone marrow aspiration during which cells will be removed 
from your bone marrow and sent for separation of different cell types.  The selected cells are to be 
re-infused into you 2 to 3 days later, as part of the clinical trial that you will be asked to participate 
in.   
 
 
I _______________________ (patient’s name) agree to the collection of specified blood  
cells by the process of bone marrow aspiration and cell separation as part of clinical  
trial HHSC/003 
 
 
 
3. Consent for Immunoselection and Possible Discard of Stem Cells 
 
You will soon undergo a stem cell collection procedure from your bone marrow. This part is to 
record your consent to the testing, storage and possible discard of excessive stem cells. 
 
I agree to my blood being tested for infections such as Hepatitis, Syphilis and AIDS.  
If any of these tests are positive I understand that I will be informed and further tests,  
counselling, and clinical follow-up will be arranged as necessary. 
 
 
I agree that any expanded stem cells in excess of the numbers required for re-infusion  
may either be used for laboratory research only or destroyed by incineration. 
 
 
I give my permission for my personal information (initials, hospital number and clinical  
code number) to be held on the National Blood Service database and for NBS  
staff to share this information with other healthcare professionals. 
 
4.  Signatures 
 
I confirm that I have understood the above information and give my consent to parts 1, 2, 
and 3. 
 
Name of Patient    ………………………………………………. 
 
Date     ………………………………………………. 
 
 
Name of person taking consent ………………………………………………. 
 
Position    ………………………………………………. 
 
Signature    ………………………………………………. 
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Date     ………………………………………………. 
 
 
Witness    ………………………………………………. 
 
Position/Relationship to Patient ………………………………………………. 
 
Signature    ………………………………………………. 
 
Date     ………………………………………………. 
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Appendix 4 – Condensed Legal RepConsent form. 
 
 
 
Protocol : HHSC/003      Legal Representative Consent Form 
(Relative, Carer or Independent Legal Representative) 
 
 
Patients Initials     Screening Number  
 
 
Stem Cell Therapy for Total Anterior Circulation Ischaemic 
Stroke 
 
1. Consent for participation in clinical trial 
(please initial boxes if they apply to you) 
 
I, _____________________________________ (name of legal representative) 
  
of, __________________________________________________ (address)                                                
 
confirm that I have read and understood the information sheet for the above  
study and the nature, purpose and possible consequences have been described  
to me. 
 
I have been given time to consider the trial and all my questions have been  
answered. 
 
I understand that I may withdraw my consent at any time, without giving a  
reason, and without my relative’s medical care or legal rights being affected. 
 
I understand that sections of any of their medical notes may be looked at  
by responsible individuals from regulatory authorities where it is relevant to my  
relative taking part in research. I give permission for these individuals to have  
access to their records. 
 
I understand that information held by the NHS and records maintained  
by the General Register/Office may be used to keep in touch with my relative  
and follow up their health status. I give permission for the study staff to  
contact the patient’s general practitioner with details about this study and  
follow up their health. 
 
I consent to the participation of ___________________________(patient’s  
name) in this research study. To my knowledge, participation would not  
conflict with his/her religious or personal beliefs. 
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2. Consent for Bone Marrow Aspiration 
 
To be read by the legal representative prior to agreeing to the process of Bone Marrow 
Aspiration. 
 
Your relative will shortly undergo the process of bone marrow aspiration during which cells will be 
removed from their bone marrow and sent for separation of different cell types.  The selected cells 
are to be re-infused into themselves 2 to 3 days later, as part of the clinical trial that they will be 
asked to participate in.   
 
I agree to the collection of specified blood cells from _______________________  
(patient’s name) by the process of bone marrow aspiration and cell separation as  
part of clinical trial HHSC/003 
 
3. Consent for Immunoselection and Possible Discard of Stem Cells 
 
Your relative will soon undergo a stem cell collection procedure from their bone marrow. This part 
is to record your consent to the testing, storage and possible discard of excessive stem cells. 
 
I agree to their blood being tested for infections such as Hepatitis, Syphilis and AIDS.  
If any of these tests are positive I understand that they will be informed and further tests,  
counselling, and clinical follow-up will be arranged as necessary. 
 
 
I agree that any expanded stem cells in excess of the numbers required for re-infusion  
may either be used for laboratory research only or destroyed by incineration. 
 
 
I give my permission for their personal information (Initials. Hospital number and  
clinical code number) to be held on the National Blood Service database and for NBS  
staff to share this information with other healthcare professionals. 
 
4.  Signatures 
 
I confirm that I have read and understood the above information and give my consent to 
parts 1, 2, and 3. 
 
 
Name of legal representative  ………………………………………………. 
 
Relationship to carer   ………………………………………………. 
 
Signature    ………………………………………………. 
 
Date     ………………………………………………. 
 
 
Name of person taking consent ………………………………………………. 
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Position    ………………………………………………. 
 
Signature    ………………………………………………. 
 
Date     ………………………………………………. 
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Appendix 5 – Competency Questionnaire 
 
Number Questions Answer 
A, B or C 
1 Who is responsible for obtaining patient consent, delivering bone 
marrow aspirate from to the JGCCT and report any incidents 
involved in the procurement/collection of aspirate. 
A) Nursing staff from the paediatric BMT unit. 
B) Clinical research fellow and Principal Investigator. 
C) Staff from the JGCCT. 
 
 
 
2 Who has overall responsibility for the bone marrow aspiration 
procedure being performed correctly? 
A) DI 
B) QP 
C) Principal Investigator for the site and the trial Chief Investigator. 
 
 
3 Before obtaining consent and scheduling the procedure the JGCCT 
must firstly be set a processing request form which once approved 
and return by the JGCCT, confirmS that they have the operational 
capacity to undertake this BM immmunoselection. 
Above statement is:  
A) True 
B) False 
 
 
 
4 The bone marrow aspiration procedure will be performed on the 
A) Grafton Stroke Ward.  
B) Grand Union Ward. 
C) Within the theatre at Hammersmith Hospital. 
 
 
5 The volume of bone marrow aspirate is limited to 20mLs in one 
single pull.   
Above statement is:  
A) True 
B) False 
 
 
6 Once the bone marrow has been collected this along with the 
necessary documentation (copy of informed consent, consumables 
log, transport log and supply of patient addressograph labels) is 
transported to the JGCCT. What documentation is involved here: 
A) Consent form and supply of patient addressograph labels. 
B) Consumables log and Transport log. 
C) Both A and B above. 
 
 
 
7 All SAEs MUST be recorded and reported immediately to the 
research team, appropriate ethics committee, Designated 
Individual, Qualified Person, and Quality Manger/BMT Programme 
Director, MHRA and the data monitoring committee for the trial. 
Above statement is:  
A) True 
B) False 
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8 Which procedure must be followed should one happen to deviate 
from this SOP: 
A) SOP: PaedBMTU-QMP-005. 
B) SOP: PaedBMTU-QMP-006. 
C) SOP: PaedBMTU-QMP-007. 
 
 
9 New operatives in this bone marrow aspirate will have to undergo 
apart from reading and completing the questionnaire of this 
procedure: 
A) Observing at least five procedures and performing two 
procedures under supervision. 
B) Read and complete the questionnaire of this procedure and read 
the SOP sections re: documentation and transport. 
C) Both A and B 
 
 
 
10 Which staff need to be aware of this procedure by reading and 
completing this questionnaire before following this procedure: 
A) Research team 
B) Haematology SpRs  
C) Both A and B 
 
 
 
 
Trainee Name (print) Job Title Trainee Signature Date 
 
 
   
Trainer Name (print) Job Title Trainer Signature Date 
 
 
   
Score, % CORRECT = 
 
(Pass = 80% or more, Failure requires repeat of Assessment with Trainer) 
Re-assessment score = 
Comments if Any: 
 
 
 
 
To be returned for Archiving to the Quality Manager Department of Paediatrics 
Haematology & BMT. 
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APPENDIX 5: STANDARD OPERATING PROCEDURE FOR CD34+ CELL 
INFUSION INTO MIDDLE CEREBRAL ARTERY 
 
Imperial College Healthcare NHS Trust 
Womens’ & Childrens’ Clinical Programme  (Paediatric Haematology & BMT) 
Quality Management Policy and Procedures 
 
Purpose: The purpose of this SOP is to ensure a safe and effective delivery of 
CD34+ cells into the middle cerebral artery (MCA). 
Scope: The scope of this procedure is to cover the scheduling, transport of 
patients and performing of middle cerebral artery cannulation.  
 
Departmental Responsibility: Quality Date Effective: Pop by QA 
Manager  
Author: Deborah Williamson     Review Date: Pop by QA 
Manager  
 
Document Control 
The Master Copy of the Quality Manual and Standard Operating Procedures (SOP’s) will 
be filed in the Quality Management Office. 
Controlled copies are numbered and stamped or water marked “Controlled Copy” in red 
ink. Any copies without this red stamp are uncontrolled and should be destroyed. 
Electronic copy will be filed within a read only folder on the Trust shared network. 
 
If this SOP appears inadequate or outdated it is the responsibility of all staff to bring this to 
the attention of their Supervisor immediately. 
 
Training Record  
The training record for this SOP is filed with the master copy of the SOP in the Quality 
Management Office. 
 
Security Statement 
This SOP is the intellectual property of the BMT Unit within the Department of Paediatrics 
(Haematology & BMT) at the St. Mary’s NHS Trust and as such, must not be circulated 
outside of the Trust without written approval from the Quality Assurance 
Manager/Programme Director  
_______________________________________________________________________ 
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4.0 Personnel & Responsibilities 
 
The clinical research fellow and Chief Investigator for the St Mary’s site will be 
responsible for: 
 
- obtaining informed consent from the patient or their representative in accordance with 
the HTA requirements (PaedBMTU-COL-500: appendix 2, 3 & 4). 
- scheduling the stem cell infusion 
- transporting the patient to and from the angiography suite 
- the delivery of stem cells to the angiography suite 
- checking the labelling of the stem cells (along with the radiologist) 
- acting as assistant in the angio suite (along with radiology staff) 
- Any clinical incidents occurring are raised, investigated and communicated according 
to the Trust procedures. 
 
The research team and patient’s medical team will be responsible for the ongoing 
assessment of the patient post-infusion. 
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Overall responsibility will be with the Chief Investigator for the site and the trial 
Principal Investigator. 
 
5.0 Background  
 
The use of haematopoietic stem cells (HSCs) for bone marrow transplantation 
is well established, and the therapeutic potential of HSCs in the regeneration of 
other non-haematopoietic tissue such as heart and skeletal muscle has also 
been explored.  There is increasing evidence that HSCs can improve 
neurological function in rodent models of ischaemic stroke, particularly when 
the cells are targeted to the area of damage, hence the rationale for this 
particular trial.  Further evidence is detailed in the Trial Protocol . 
 
Project HHSC/003 (A phase I/II safety and tolerability study following the autologous 
infusion of CD34+ selected haematopoetic cells into patients with acute total anterior 
circulation ischaemi stroke). 
 
BM immunoselection and tissue release is carried out under a MHRA IMP 
manufacturer’s authorisation and may be subject to audit for compliance by the 
Qualified Person and/or Designated Individual or any of the relevant Regulatory 
Agencies including the MHRA Clinical Trials office. Administration of Immunoselected 
cells is in accordance with the requirements of the Clinical Trials Authorisation and 
local research ethics approval. 
 
 
6.0 Definitions 
 
BM = Bone Marrow 
SOP = Standard Operating Procedure 
HSC = Haematopoietic Stem Cell 
CRF = Case report form 
SAE = Serious Adverse Event 
HTA = Human Tissue Authority  
DI = Designated Individual 
QP = Qualified Person 
 
 
4.0 Health & Safety 
 
A detailed risk assessment for the patient is given in the current Trial Protocol ..   
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.Appropriate safety procedures will be followed: 
 
- Wearing of appropriate protective clothing (e.g. apron, gloves etc.), is 
essential 
- Disposal of all used needles and other sharp objects immediately into an 
approved sharps container.  
 
All staff will follow Imperial College NHS Trust Health and Safety and Infection control 
procedures. 
 
5.0 Equipment/Documentation 
 
5.1 Equipment 
 
Equipment for the procedure will be provided by the radiology department, and 
appropriate invoicing will be arranged between the research team and radiology staff. 
 
5.2 Documentation 
 
The documentation provided relating to the procedure will be: 
 
 signed informed consent form 
 consumables log sheet (see Appendix 1) 
 Trial CRF 
 SAE report (if required) 
 Stem Cell and Immunotherapy request for clinical use’ form (JGCCT – FRM-
004) 
 
6.0 Procedure  
 
6.1 Scheduling the Stem Cell Infusion 
The clinical research fellow will liase directly with the JGCCT regarding the precise 
timing for collection and FAX a completed ‘StemCell and Immunotherapy request for 
clinical use’ form (JGCCT – FRM-004) to the facility. 
 
The clinical research fellow will be responsible for contacting the radiology department 
and providing as much advance notice as possible.  Prior to infusion, the patient will 
have a cerebral angiogram to ensure that the cerebral anatomy is suitable for infusion.  
All procedures will be booked though the St Mary’s PACS system. 
 
6.2 Materials to be taken to the Angio Suite 
 
The clinical research fellow is responsible for taking to theatre: 
 
 copy of signed consent form 
 consumables form 
 stem cell infusate (provided in a 20ml syringe) 
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6.3 Stem Cell Infusion 
 
This is the responsibility of the interventional radiologist.  He/she will be responsible for 
cannulating the middle cerebral artery and infusing the stem cell preparation into the 
patient.  Patients will have previously been selected for the trial on the basis of 
inclusion criteria and on a suitable cerebral angiogram. 
  
 The patient will be laid flat on a table in the angio suite 
 The femoral artery will be cannulated using a standard Seldinger technique. 
 Under radiological guidance, the middle cerebral artery will be cannulated 
 Following checking of the infusate label by the clinical research fellow and the 
radiologist, the stem cells will be infused 
 Full clinical monitoring of the patient will be observed throughout 
 Details of the procedure will be recorded in the Trial CRF, and the consumables 
used will be completed in the consumables log sheet. 
 The patient will then be transported back to the acute stroke Unit, where they 
will undergo 2 hourly neuro-observations for a period of  at least12 hours 
 
6.4 SAE Reporting 
 
All SAEs will be recorded in the approved SAE form, and reported immediately to the 
research team, appropriate ethics committee, Designated Individual, Qualified Person, 
and Quality Manger/BMT Programme Director, MHRA and the data monitoring 
committee for the trial. 
 
6.5 Deviation from SOP 
 
Any deviations from this SOP must be documented and approved according to SOP 
PaedBMTU-QMP-006. 
 
6.0 Training and Competency Assessment 
 
Type of Training No specific training required for the use of this SOP, just 
awareness of this SOP. 
 
Method of competency 
assessment for “procedure” 
N/A for Policy/Guidelines.  
 
List Staff required for Training 
and Competency Assessment 
Research team, as well as interventional radiologist 
 
Who is to perform this training N/A 
 
Evidence Log of 
Training/Competency 
Assessment 
Staff must firstly complete the Record Training & 
Comprehension form. 
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7.0 References 
 
N/A 
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Appendix 1: Consumables Log Sheet 
 
 
 
Angiography Suite, St Marys Hospital 
 
Staff present: 
 
Date: 
 
Time: 
 
Patient Name: 
Date of Birth: 
Hospital Number: 
Trial Number: 
 
 
Consumables Used: 
 
Item 
 
Lot no. Expiry Date Cost 
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APPENDIX 6: STANDARD OPERATING PROCEDURE FOR DEVIATING FROM 
PROTOCOL 
 
 
Imperial College Healthcare NHS  
 
Imperial College Healthcare Trust 
Womens’ & Childrens’ Clinical Programme Group (Paediatric Haematology & 
BMT) Quality Management Policy and Procedures 
 
 
Purpose: This policy describes the steps to take when handling deviating such as those 
from an SOP (Type Procedure), product specification, equipment failure etc. 
Scope:  Deviations are unplanned events which may arise but when identified must be 
investigated in order to determine the consequences, the possible potential harm caused, 
requirements for any corrective actions and identification of the root cause. This must be 
carried out in order to document the deviation, obtain confirmation, and make aware the 
steps taken/to be taken following the deviation, and to prevent recurrence 
 
 
Departmental Responsibility: Clinical Date Effective: pop by QAM 
 
Author: Kirtash Patel Review Date: pop by QAM 
 
Document Control 
The Master Copy of the Quality Manual and Standard Operating Procedures (SOP’s) will 
be filed in the Quality Management Office. 
Controlled copies are numbered and stamped or water marked “Controlled Copy” in red 
ink. 
Any copies without this red stamp are uncontrolled and should be destroyed. Electronic 
copy will be filed within a read only folder on the Trust shared network. 
 
If this SOP appears inadequate or outdated it is the responsibility of all staff to bring this 
to the attention of their Supervisor immediately. 
 
Training Record 
The training record for this SOP is filed with the master copy of the SOP in the Quality 
Management Office. 
 
Security Statement 
This SOP is the intellectual property of the Department of Paediatrics Haematology & 
BMT and as such, must not be circulated outside of the Trust without written approval 
from the Quality Assurance Manager/Programme Director 
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 6.2 Generation of Results 3 
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9.0 Revision History 4 
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 Appendices  
 
 
1.0 Personnel & Responsibilities 
 
These guidelines apply to any member of staff within the SCT Unit and the 
Department of Haematology at the St. Mary’s Hospital, who has caused, is involved 
or significant has identified a deviation from a SOP. 
 
It is the responsibility of all staff to ensure that these guidelines are followed. 
 
2.0 Background 
 
 
Undoubtedly deviations from biological variations, product specification, method, 
protocol, equipment failure or SOP of type "procedure" will occur. However, it is equally 
important that when they do arise, the correct steps are taken to: 
 
1. assess the impact (consequences) of such deviation, with other colleagues/senior staff. 
 
2. determine possible potential harm caused. 
 
3. assess the need to rectify the deviation, in so doing ensuring that the correct 
corrective action(s) are implemented. 
 
4. identify the root cause to prevent recurrence of the deviation. 
 
5. obtain approval of the steps taken/to be taken following the deviation 
 
6. document the deviation, especially for future reference but also in case 
complications/issues arise at a later date. 
 
 
3.0 Definitions 
 
Significant deviations are unplanned or planned events that have taken place 
unknowingly or knowingly when performing a process or task using a product 
specification, method, protocol, equipment failure or SOP of type "procedure" which is 
likely to adversely affect the outcome, quality, or safety. 
 
Examples of a few significant deviations are: 
  Thawed cryopreserved cells not infused within recommended time 
  Failing to meet a predefined product specification, for example TNC dose less 
than required for a bone marrow harvest 
  Significant loss of material such as spillage during processing 
  Positive microbiological sterility at any stage of processing 
  Dry shipper used for infusion not fully charged and thaws during shipping 
  Out of date consumables used 
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  GMP facility differential pressures out of limits and rooms used for processing 
  GMP environmental monitoring out of limits and rooms used for processing 
  Biohazard label not attached to harvests when IDM positive or testing not 
done/complete 
  Equipment failure during a procedure for example due to power failure 
  Conditioning Protocols are not followed according to the administration of drug 
products as specified within the procedures. 
  Consent for mobilising chemotherapy. 
  Not irradiating cellular blood products with 25 Gy before transfusion to a SCT patient. 
  Not removing a Hickman line as soon as possible after transplant resulting in 
infection. 
  Etc.. 
 
 
4.0 Health & Safety 
 
N/A 
 
5.0 Equipment/Documentation 
 
Reporting and Approval of deviations from an SOP form 
 
6.0 Procedure 
 
As soon as a possible significant deviation is identified the person that has identified 
this possible significant deviation must discuss and confirm with a senior member of 
staff i.e. lab staff with the head of Processing Department or Head of Quality 
Testing/SCI Lab Director, Clinical staff with Ward Consultant and Nurses with Senior 
Nurses) and then complete the "Reporting and Approval of Deviations from SOPs 
form" (appendix 1). 
 
All significant deviations must be reported and documented using the Reporting and 
Approval of Deviations from SOPs form (appendix 1). Minor deviations that do not 
adversely affect the outcome, quality, or safety are not required to be reported. If one is 
unsure whether a deviation is minor or significant discuss the deviation with a senior 
member of staff or the section head. 
 
A full investigation must be carried out, identifying any paternal safety concerns/issues, 
what the root cause was, any corrective actions required, preventative actions necessary 
to prevent reoccurrence, etc. This form must be approved by the relevant director of the 
facility where the deviation took place (BMT programme director, Collection Facility 
Director or SCI Laboratory Director). 
 
Should any significant deviation relate to a specific patient then the deviation and outcome 
of the assessment/investigation much also be documented in that patients casenotes (or a 
copy of the Reporting and Approval of Deviations from SOPs form, placed within the 
relevant section of that patient's casenotes. 
 
If the significant deviation is regarded as an adverse event, then a Clinical Incident form 
should also be completed, as prompted within the Reporting and Approval of Deviations 
from SOPs form. 
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Any significant deviation that warrants notification to the HTA must be approved and 
communicated by the BMT Programme Director, Collection Facility Director or SCI 
Laboratory Director. 
 
6.1 Generation of Results 
 
Where the procedure generates results then the procedure must state 
"expected results" and "range of acceptable outcomes". Not applicable for 
this procedure. 
 
7.0 Training & Comprehension or Competency Assessment 
 
Type of Training No training required for this use of this SOP 
Method of competency 
assessment for 
“procedure” 
N/A for Policy/Guidelines. 
List Staff required for 
Training and 
Competency Assessment 
To ensure that this process is followed just senior 
staff - Senior/head Nurses, Consultants and BMT 
coordinators, as reference to this SOP is made 
within all SOPs of Type 
Procedure 
Who is to perform this 
training 
N/A. 
Evidence Log of 
Training/Competency 
Assessment 
Before using this SOP relevant staff must firstly 
complete the Records Training & Competency 
record. 
 
 
 
8.0 References 
 
SOP: PaedBMTU-QMP-002 Adverse Reactions (Clinical Incidents) 
 
9.0 Revision history 
 
Issue Change 
1.0 First Issue 
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10.0 Managerial Approval: 
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Author: 
 
K. Patel 
  
Quality Manager 
 
Reviewers 
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Reporting and Approval of Deviations from SOPs form 
 
Deviation Reported by:  
Date Deviation Identified:  
With reference to which SOP, procedure, 
document  has the deviation taken place 
from: 
 
 
 
Detail of Deviation: 
 
 
 
 
 
What if any are the consequences/potential harm of this deviation: 
 
 
 
 
 
 
Any corrective actions required to rectify the deviation: 
 
 
 
 
 
 
If known what was the root cause that instigated this deviation: 
 
 
 
 
 
 
Any preventative measures initiated: 
 
 
 
 
 
 
Has this deviation been documented within 
the casenotes of the patient affected. 
Yes / No / N/A (give reason) 
Has an Incident form been complete? Yes / No 
Does this deviation require reporting to the 
HTA? 
Yes/No 
Approved By Sign: 
(BMT programme director, Collection 
Facility 
 
 
Date:  
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Banerjee S, Bentley P, Hamady M, Gordon M, Davis J, Marley S, Williamson D, McColgan P, 
Mehta A, Waldman A, Quest R, McRobbie D, Shlebak A, Nicholls J, Habib N, Chataway J. 
 Poster presentation at UK Stroke Forum, Glasgow, 2011 
 
 
Phase I trial of autologous CD34+ haematopoietic stem cells in acute ischaemic stroke. Banerjee S, 
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